Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2017 | Mar. 15, 2018 | Jun. 30, 2017 | |
Document And Entity Information [Abstract] | |||
Entity Registrant Name | Akers Biosciences, Inc. | ||
Entity Central Index Key | 1,321,834 | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2017 | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Entity a Well-known Seasoned Issuer | No | ||
Entity a Voluntary Filer | No | ||
Entity's Reporting Status Current | Yes | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Public Float | $ 10,201,326 | ||
Entity Common Stock, Shares Outstanding | 81,973,964 | ||
Trading symbol | AKER | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2,017 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Current Assets | ||
Cash | $ 438,432 | $ 72,700 |
Marketable Securities | 5,011,607 | 50,001 |
Trade Receivables, net | 1,490,985 | 601,271 |
Trade Receivables - Related Party, net | 125,001 | 31,892 |
Deposits and other receivables | 16,590 | 23,782 |
Inventories, net | 1,845,281 | 2,036,521 |
Prepaid expenses | 145,488 | 168,277 |
Prepaid expenses - Related Party | 251,499 | 202,500 |
Total Current Assets | 9,324,883 | 3,186,944 |
Non-Current Assets | ||
Prepaid expenses - Related Party | 120,118 | 270,183 |
Property, Plant and Equipment, net | 235,113 | 259,392 |
Intangible Assets, net | 1,130,667 | 1,301,775 |
Other Assets | 76,093 | 66,813 |
Total Non-Current Assets | 1,561,991 | 1,898,163 |
Total Assets | 10,886,874 | 5,085,107 |
Current Liabilities | ||
Trade and Other Payables | 1,733,216 | 1,463,363 |
Trade and Other Payables - Related Party | 39,821 | 234,067 |
Total Current Liabilities | 1,773,037 | 1,697,430 |
Total Liabilities | 1,773,037 | 1,697,430 |
STOCKHOLDERS' EQUITY | ||
Convertible Preferred Stock, No par value, 50,000,000 shares authorized, 1,755 and 0 shares issued and outstanding as of December 31, 2017 and 2016 | 1,755,000 | |
Common Stock, No par value, 500,000,000 shares authorized, 44,220,552 and 5,452,545 issued and outstanding as of December 31, 2017 and 2016 | 110,647,169 | 100,891,786 |
Deferred Compensation | (3,469) | (24,572) |
Accumulated Deficit | (103,284,863) | (97,479,537) |
Accumulated Other Comprehensive Income | ||
Total Stockholders' Equity | 9,113,837 | 3,387,677 |
Total Liabilities and Stockholders' Equity | $ 10,886,874 | $ 5,085,107 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2017 | Dec. 31, 2016 |
Statement of Financial Position [Abstract] | ||
Convertible preferred stock, no par value | ||
Convertible preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Convertible preferred stock, shares issued | 1,755 | 0 |
Convertible preferred stock, shares outstanding | 1,755 | 0 |
Common stock, no par value | ||
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 44,220,552 | 5,452,545 |
Common stock, shares outstanding | 44,220,552 | 5,452,545 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Revenues: | ||
Product Revenue | $ 3,754,896 | $ 2,956,782 |
Product Revenue - Related party | 124,631 | 380 |
License & Service Revenue | 50,000 | 3,750 |
Total Revenues | 3,929,527 | 2,960,912 |
Cost of Sales: | ||
Product Cost of Sales | (1,419,963) | (1,083,087) |
Gross Income | 2,509,564 | 1,877,825 |
Administrative Expenses | 4,082,313 | 3,008,811 |
Sales and Marketing Expenses | 1,846,445 | 1,983,428 |
Sales and Marketing Expenses - Related Party | 202,126 | 153,854 |
Research and Development Expenses | 1,237,384 | 1,188,868 |
Research and Development Expenses - Related Party | 22,994 | |
Reversal of Allowance Related parties | (1,299,609) | |
Amortization of Non-Current Assets | 171,108 | 171,108 |
(Loss)/Income from Operations | (5,052,806) | (3,328,635) |
Other (Income)/Expenses | ||
Foreign Currency Transaction (Gain)/Loss | (1,659) | (3,398) |
Interest and Dividend Income | (10,753) | (21,699) |
Warrant Modification Expense | 764,932 | |
Total Other (Income)/Expense | 752,520 | (25,097) |
Loss Before Income Taxes | (5,805,326) | (3,303,538) |
Income Tax Benefit | ||
Net Loss Attributable to Common Stockholders | (5,805,326) | (3,303,538) |
Other Comprehensive Income | ||
Net Unrealized Gain on Marketable Securities | 6,231 | |
Total Other Comprehensive Income | 6,231 | |
Comprehensive Loss | $ (5,805,326) | $ (3,297,307) |
Basic and Diluted loss per common share | $ (0.61) | $ (0.61) |
Weighted average basic and diluted common shares outstanding | 9,494,977 | 5,430,205 |
Consolidated Statement of Chang
Consolidated Statement of Changes in Shareholder’s Equity - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Deferred Compensation [Member] | Accumulated Deficit [Member] | Accumulated Other Comprehensive Income/(Loss) [Member] | Total |
Balance at Dec. 31, 2015 | $ 100,785,408 | $ (94,175,999) | $ (6,231) | $ 6,603,178 | ||
Balance, shares at Dec. 31, 2015 | 5,425,045 | |||||
Net loss | (3,303,538) | (3,303,538) | ||||
Issuance of restricted common stock to officers | $ 54,725 | (54,725) | ||||
Issuance of restricted common stock to officers, shares | 27,500 | |||||
Amortization of deferred compensation | 30,153 | 30,153 | ||||
Issuance of Non-Qualified Stock Options for key Employees | 27,977 | 27,977 | ||||
Issuance of Non-Qualified Stock Options for services from non-employees | 23,676 | 23,676 | ||||
Net unrealized gain on marketable securities | 6,231 | 6,231 | ||||
Balance at Dec. 31, 2016 | $ 100,891,786 | (24,572) | (97,479,537) | 3,387,677 | ||
Balance, shares at Dec. 31, 2016 | 5,452,545 | |||||
Net loss | (5,805,326) | (5,805,326) | ||||
Amortization of deferred compensation | $ 21,103 | $ 21,103 | ||||
Share register adjustment | (1) | |||||
Public offering of common stock, net of offering costs of $494,406 | $ 1,652,994 | $ 1,652,994 | ||||
Public offering of common stock, net of offering costs of $494,406, shares | 1,789,500 | |||||
Private offering of common stock, net of offering costs of $267,443 | $ 1,760,317 | 1,760,317 | ||||
Private offering of common stock, net of offering costs of $267,443, shares | 1,448,400 | |||||
Public offering of common and preferred stock, net of offering costs of $834,414 | $ 3,675,000 | $ 2,390,586 | 6,065,586 | |||
Public offering of common and preferred stock, net of offering costs of $834,414, shares | 3,675 | 21,500,000 | ||||
Warrant Modification | $ 764,932 | 764,932 | ||||
Exercise of warrants for common stock | $ 981,948 | 981,948 | ||||
Exercise of warrants for common stock, shares | 925,000 | |||||
Conversion of preferred stock to common stock | $ (1,920,000) | $ 1,920,000 | ||||
Conversion of preferred stock to common stock, shares | (1,920) | 12,800,001 | ||||
Issuance of stock grants to officers | $ 163,924 | 163,924 | ||||
Issuance of stock grants to officers, shares | 186,277 | |||||
Issuance of stock grants to key employees | $ 95,770 | 95,770 | ||||
Issuance of stock grants to key employees, shares | 108,830 | |||||
Issuance of non-qualified stock options to key employees | $ 17,274 | 17,274 | ||||
Issuance of non-qualified stock options for services to non-employees | 2,183 | 2,183 | ||||
Issuance of restricted stock for services for non-employees | $ 5,455 | 5,455 | ||||
Issuance of restricted stock for services for non-employees, shares | 10,000 | |||||
Balance at Dec. 31, 2017 | $ 1,755,000 | $ 110,647,169 | $ (3,469) | $ (103,284,863) | $ 9,113,837 | |
Balance, shares at Dec. 31, 2017 | 1,755 | 44,220,552 |
Consolidated Statement of Chan6
Consolidated Statement of Changes in Shareholder’s Equity (Parenthetical) | Dec. 31, 2017USD ($) |
Net offering cost | $ 834,414 |
Public Offering [Member] | |
Net offering cost | 494,406 |
Private Offering[Member] | |
Net offering cost | $ 267,443 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Cash flows from operating activities | ||
Net loss | $ (5,805,326) | $ (3,303,538) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Accrued income on marketable securities | (1,412) | 14,244 |
Depreciation and amortization | 249,894 | 286,162 |
Reserve and write-off for obsolete inventory | 32,333 | |
Allowance for/(Reversal) of doubtful accounts | 450,000 | (1,153,413) |
Expenses related to modification of warrants | 764,932 | |
Amortization of deferred compensation | 21,103 | 30,153 |
Share based compensation to employees - options | 17,274 | 27,977 |
Share based compensation to employees - restricted stock | 95,770 | |
Share based compensation to officers - restricted stock | 163,924 | |
Share based compensation to non-employees - options | 2,183 | 23,676 |
Share based compensation to non-employees - restricted stock | 5,455 | |
Changes in assets and liabilities: | ||
Increase in trade receivables | (1,339,714) | (138,272) |
Increase in trade receivables - related party | (93,109) | (380) |
Decrease in deposits and other receivables | 7,192 | 71,795 |
(Increase)/decrease in inventories | 165,118 | (187,200) |
Decrease in prepaid expenses | 22,789 | 17,689 |
Decrease in prepaid expenses - related party | 101,066 | 76,927 |
Increase in other assets | (9,280) | |
Increase/(decrease) in trade and other payables | 269,853 | (205,368) |
Increase/(decrease) in trade and other payables - related party | (194,246) | 234,067 |
Net cash used in operating activities | (5,080,412) | (4,173,148) |
Cash flows from investing activities | ||
Purchases of property, plant and equipment | (54,507) | (123,301) |
Purchases of marketable securities | (7,709,341) | (35,944) |
Proceeds from sale of marketable securities | 2,749,147 | 4,003,034 |
Net cash provided/(consumed) by investing activities | (5,014,701) | 3,843,789 |
Cash flows from financing activities | ||
Net proceeds from issuance of common stock | 5,803,897 | |
Proceeds from issuance of preferred stock | 3,675,000 | |
Net proceeds from exercise of warrants for common stock | 981,948 | |
Net cash provided by financing activities | 10,460,845 | |
Net increase/(decrease) in cash | 365,732 | (329,359) |
Cash at beginning of year | 72,700 | 402,059 |
Cash at end of year | 438,432 | 72,700 |
Supplemental Schedule of Non-Cash Financing and Investing Activities | ||
Issuance of restricted common stock grants to officers | 54,725 | |
Net unrealized gains on marketable securities | 6,231 | |
Settlement of note receivable in the form of inventory | 750,000 | |
Settlement of note receivable in the form of prepaid expense | $ 549,609 |
Nature of Business
Nature of Business | 12 Months Ended |
Dec. 31, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Business | Note 1 - Nature of Business (a) Reporting Entity The accompanying financial statements have been prepared by Akers Biosciences, Inc. (“Akers” or the “Company”), a company domiciled in the United States of America. The address of the Company’s registered office is 201 Grove Road, West Deptford, New Jersey, 08086. The Company is incorporated in the United States of America under the laws of the State of New Jersey. The consolidated financial statements include two dormant subsidiaries, Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation. All material intercompany transactions have been eliminated upon consolidation. (b) Nature of Business The Company’s primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s main products are a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body. When the Company enters into an agreement with a new distributor it typically requires an upfront licensing fee to be paid for the right to sell the Company’s products in specific markets. |
Basis of Presentation
Basis of Presentation | 12 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Note 2 - Basis of Presentation (a) Statement of Compliance The consolidated financial statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (US GAAP). The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements. (b) Use of Estimates and Judgments The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for revenue recognition, allowances for doubtful accounts, inventory write-downs, impairment of intangible assets and valuation of share based payments. (c) Functional and Presentation Currency These consolidated financial statements are presented in U.S. Dollars, which is the Company’s functional currency. All financial information presented in U.S. Dollars has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from loans and cash balances denominated in Foreign Currencies, are recorded in the consolidated statement of operations and comprehensive loss. (d) Comprehensive Income (Loss) The Company follows Financial Accounting Standards Board Accounting Standards Codification (FASB ASC) 220 in reporting comprehensive income (loss). Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | Note 3 - Significant Accounting Policies (a) Cash and Cash Equivalents Cash and cash equivalents comprise cash balances. The Company considers all highly liquid investments, which include short-term bank deposits (up to 3 months from date of deposit) that are not restricted as to withdrawal date or use, to be cash equivalents. Bank overdrafts are shown as part of trade and other payables in the consolidated balance sheet. (b) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables. The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their short maturities. The fair value of marketable securities is described in Note 3(c). (c) Fair Value Measurement – Marketable Securities The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows: Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 Inputs to the valuation methodology include ● quoted prices for similar assets or liabilities in active markets; ● quoted prices for identical or similar assets or liabilities in inactive markets; ● inputs other than quoted prices that are observable for the asset or liability; ● inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs. (d) Trade Receivables, Trade Receivables – Related Party and Allowance for Doubtful Accounts The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature. The normal credit terms extended to customers ranges between 30 and 90 days. Credit terms longer than these may be extended after considering the credit worthiness of the customers and the business requirements. The Company reviews all receivables that exceed terms and establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade and other receivables. A considerable amount of judgment is required in assessing the amount of allowance. The Company considers the historical level of credit losses, makes judgments about the credit worthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. As of December 31, 2017 and 2016, allowances for doubtful accounts for trade receivables were $596,196 and $1,010,196. Bad debt expenses for trade receivables were $494,436 and $146,196 for the years ended December 31, 2017 and 2016. The credit comprises the reversal of an allowance for bad debts expense – related party of $1,299,609 and an allowance for bad debts for an external party of $146,195 included in the administrative expenses for the year ended December 31, 2016. Included in the allowance for doubtful accounts as of December 31, 2016 is $864,000 being an allowance for doubtful account of a trade receivable from a related party written off against the trade receivable in the year ended December 31, 2017. As of December 31, 2017 and 2016, the aging of trade receivables and trade receivables – related party was as follows: December 31, Aging Period 2017 % 2016 % Current (Notes 6 & 16) 1,808,449 81 % 464,365 28 % 01-30 Days 79,535 4 % 43,223 3 % 31-60 Days 20,154 1 % 39,203 2 % 61-90 Days 25,100 1 % 6,150 0 % >90 Days 278,944 13 % 1,090,418 67 % Subtotal 2,212,182 1,643,359 Bad Debts Allowance (596,196 ) (1,010,196 ) Total $ 1,615,986 $ 633,163 Average Days in Receivable 205.48 202.58 The aging above represents the number of days that the account receivable balance exceeds the credit terms. Included in the current category is accounts receivable of $570,800 and $- as of December 31, 2017 and December 31, 2016 with payment terms extended to 180 days. (e) Concentration of Credit Risk The Company is exposed to credit risk in the normal course of business primarily related to trade receivables and cash and cash equivalents. All of the Company’s cash is maintained with Fulton Bank of New Jersey, Bank of America, NA and PayPal. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company placed $426,927 and $67,865 with Fulton Bank of New Jersey, $7,915 and $795 with Bank of America, NA and $3,590 and $4,040 with PayPal as of December 31, 2017 and 2016. No losses have been incurred in these accounts. Concentration of credit risk with respect to trade receivables exists as approximately 62% of the Company’s product revenue is generated by three customers. These customers accounted for 51% of trade receivables as of December 31, 2017. To limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition. (f) Inventories Inventories are measured at the lower of cost or net realizable value. The cost of inventories is based on the weighted-average principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, costs include an appropriate share of production overheads based on normal operating capacity. (g) Property, Plant and Equipment Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized within “other income” in the consolidated statement of operations and comprehensive loss. Depreciation is recognized in profit and loss on the accelerated basis over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of the lease term or their useful lives. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Plant and equipment 5-12 Furniture and fixtures 5-10 Computer equipment & software 3-5 Shorter of the Leasehold Improvements remaining lease or estimated useful life Depreciation methods, useful lives and residual values are reviewed at each reporting date. (h) Intangible Assets (i) Patents and Trade Secrets The Company has developed or acquired several diagnostic tests that can detect the presence of various substances in a person’s breath, blood, urine and saliva. Propriety protection for the Company’s products, technology and process is important to its competitive position. As of December 31, 2017, the Company has ten patents from the United States Patent Office in effect (9,383,368; 7,896,167; 8,097,171; 8,003,061; 8,425,859; 8,871,521; 8,808,639; D691,056; D691,057 and D691,058). Other patents are in effect in Australia through the Design Registry (348,310; 348,311 and 348,312), European Union Patents 1793906, 2684025, 002216895-0001; 002216895-0002 and 002216895-0003), in Hong Kong (HK11004006) and in Japan (1,515,170; 4,885,134; 4,931,821 5,775,790, and 6023096). Patents are in the national phase of prosecution in many Patent Cooperation Treaty participating countries. Additional proprietary technology consists of numerous different inventions. The Company intends to file additional patent applications, where appropriate, relating to new products, technologies and their use in the U.S., European and Asian markets. Management intends to protect all other intellectual property (e.g. copyrights, trademarks and trade secrets) using all legal remedies available to the Company. (ii) Patent Costs Costs associated with applying for patents are capitalized as patent costs. Once the patents are approved, the respective costs are amortized over their estimated useful lives (maximum of 17 years) on a straight-line basis. Patent pending costs for patents that are not approved are charged to operations the year the patent is rejected. In addition, patents may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life. (iii) Other Intangible Assets Other intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses. (iv) Amortization Amortization is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Patents and trademarks 12-17 Customer lists 5 (i) Recoverability of Long Lived Assets In accordance with FASB ASC 360-10-35 “Impairment or Disposal of Long-lived Assets”, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges) and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets. (j) Investments In accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company’s ability to significantly influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the time of the investment based upon several factors including, but not limited to the following: a) Representation on the Board of Directors b) Participation in policy-making processes c) Material intra-entity transactions d) Interchange of management personnel e) Technological dependencies f) Extent of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small. The Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the cost method. Investments recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company’s ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for using the cost method to the equity method of valuation. On March 9, 2015, the Company contributed capital of $64,675 in Hainan Savy Akers Biosciences, Ltd., a company incorporated in the People’s Republic of China, resulting in a 19.9% ownership interest. The contribution was adjusted downward to $64,091 on April 8, 2015; the net effect of the currency conversion when the contribution was processed in Hainan. This is included in other assets in the Consolidated Balance Sheet as of December 31, 2017 and 2016 and is accounted for using the cost method. (k) Revenue Recognition In accordance with FASB ASC 605, the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) the collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales when title passes to the customer based on shipping terms. The Company typically does not accept returns nor offer charge backs or rebates except for certain distributors. Revenue recorded is net of any discount, rebate or sales return. The accrual for estimated sales returns was $- as of December 31, 2017 and 2016. The Company implemented a standard dealer cost model during the year ended December 31, 2016 which includes a provision for rebates to the distributors under limited circumstances. The Company established an accrual of $126,471 and $41,120, which is a reduction of revenue as of December 31, 2017 and 2016. Accounts receivable will be reduced when the rebates are applied by the customer. The Company recognized $372,664 and $471,949 during the years ended December 31, 2017 and 2016 for rebates, which is included as a reduction of product revenue in the Consolidated Statement of Operations and Comprehensive Loss. License fee revenue is recognized on a straight-line basis over the term of the license agreement. When the Company enters into arrangements that contain more than one deliverable, the Company allocates revenue to the separate elements under the arrangement based on their relative selling prices in accordance with FASB ASC 605-25. (l) Income Taxes The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense or benefit is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. (m) Shipping and Handling Fees and Costs The Company charges actual shipping plus a handling fee to customers, which amounted to $62,049 and $54,928 for the years ended December 31, 2017 and 2016. These fees are classified as part of product revenue in the Consolidated Statement of Operations and Comprehensive Loss. Shipping and other related delivery costs, including those for incoming raw materials are classified as part of the cost of net revenue, which amounted to $136,145 and $138,662 for the years ended December 31, 2017 and 2016. (n) Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred. (o) Stock-based Payments The Company accounts for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over shorter of the period over which services are to be received or the vesting period. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees”. Under FASB ASC 505-50, the Company determines the fair value of the stock warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company estimates the fair value of stock-based awards to non-employees on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the period which services are to be received. At the end of each financial reporting period, prior to vesting or prior to completion of services, the fair value of equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurement until the equity based payments are fully vested or the service is completed. (p) Basic and Diluted Earnings per Share of Common Stock Basic earnings per common share are based on the weighted average number of shares outstanding during the periods presented. Diluted earnings per share are computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive, i.e. the exercise prices of the outstanding stock options were greater than the market price of the common stock. (q) Recently Adopted Accounting Pronouncements As of December 31, 2017 and for the year then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements. (r) Recently Issued Accounting Pronouncements Not Yet Adopted As the Company is an emerging growth company, it has elected to adopt recently issued standards based on effective dates applicable to nonpublic entities. All effective dates as mentioned in the following paragraphs refer to that applicable to nonpublic entities. In May 2014 and April 2016, the FASB issued ASU No. 2014-09 and ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, FASB issued ASU 2015-14 which deferred the effective date of Update 2014-09 to annual reporting periods beginning after December 15, 2018 and interim reporting periods within annual reporting periods beginning after December 15, 2019. Early application is permitted as of annual reporting periods beginning after December 15, 2016 including interim reporting periods within that reporting period. The Company is currently evaluating the effect of the amendments but it does not anticipate a material impact of its financial statements. The Company expects to use the modified retrospective adoption method. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation |
Management Plan
Management Plan | 12 Months Ended |
Dec. 31, 2017 | |
Management Plan | |
Management Plan | Note 4 – Management Plan Historically, the Company has relied upon public offerings and private placements of common stock to raise operating capital. During the year ended December 31, 2017, the Company raised $9,478,897, net of expenses, in public and private offerings and an additional $981,948, net of expenses, from the exercise of warrants (Note 13). As of March 16, 2018, the Company had realized an additional $4,909,081 from the exercise of warrants, had cash and marketable securities of approximately $8.94 million and working capital of approximately $11.19 million. The 2017-19 Strategic Business Plan (“Strat Plan”) was presented to and approved by the Board of Directors on December 12, 2016. The plan outlines the Company’s business objectives for the next three years and sets measurable targets for new product releases, sales and marketing programs to increase market penetration for the Company’s products and operational expense management. Implementation of the Strat Plan began in January 2017 and management remains confident that the objectives are achievable. The Company’s Go To Market (“GTM”) plan, revised annually, supports the implementation of the Strat Plan by defining specific tasks, products and customer targets designed to achieve the Plan’s revenue goals. The Company anticipates achieving a cash-flow positive position during the second quarter of 2018 based upon the revenue targets as outlined in the GTM and Strat Plan. During the year ended December 31, 2016, the Company significantly reduced operating expenses through a systematic review of operations throughout the organization. As a result, the Company achieved a reduction in its weekly operating cash requirements of approximately 19% to $80,253 (2015: $98,699). The Company has achieved the reduction in weekly cash requirements by renegotiating contracts with key consultants and canceling consulting agreements where the cost-benefits are negligible, working with vendors to reduce or eliminate minimum purchasing requirements, to extend payment terms and re-sourcing materials when necessary to reduce costs. Production cost savings, especially direct manufacturing costs, have been realized by utilizing sub-contractors to perform labor intensive production processes. This improves efficiency for our manufacturing staff, allowing them to concentrate their efforts on more complex assembly and production tasks. During the year ended December 31, 2017, the Company’s average weekly operating cash requirement increased to $97,700 (2016: $80,253). The increase resulted from payments to vendors and sub-contractors included in the December 31, 2016 accounts payable balance, a significant royalty payment that had been deferred in 2016 as part of a legal settlement, significantly higher professional service fees and other payments for contractual obligations. The Company anticipates the cash requirements to remain in the range of $95,000 to $100,000 per week throughout 2018. Barring any unforeseen circumstances, the Company believes that it is probable that it will be able to meet its obligations as they fall due within one year after the financial statements are issued. |
Fair Value Measurement - Market
Fair Value Measurement - Marketable Securities | 12 Months Ended |
Dec. 31, 2017 | |
Investments, Debt and Equity Securities [Abstract] | |
Fair Value Measurement - Marketable Securities | Note 5 - Fair Value Measurement - Marketable Securities Following is a description of the valuation methodologies used for assets measured at fair value as of December 31, 2017 and 2016. U.S. Agency Securities and Corporate and Municipal Securities: As of December 31, 2017 Accrued Unrealized Unrealized Fair Cost Income Gains Losses Value Level 2: Money market funds $ 5,165 $ 161 $ - $ - $ 5,326 Municipal securities 5,005,000 1,281 - - 5,006,281 Total Level 2: 5,010,165 1,442 - - 5,011,607 Total: $ 5,010,165 $ 1,442 $ - $ - $ 5,011,607 As of December 31, 2016 Cost Accrued Income Unrealized Gains Unrealized Losses Fair Value Level 2: Money market funds $ 29,657 $ 15 $ - $ - $ 29,672 Municipal securities 20,314 15 - - 20,329 Total Level 2: 49,971 30 - - 50,001 Total: $ 49,971 $ 30 $ - $ - $ 50,001 Marketable securities are classified as available for sale. The securities are valued at fair market value. Maturities of the securities are less than one year. Unrealized gains relating to the available for sale investment securities were recorded in the Consolidated Statement of Changes in Shareholders’ Equity as comprehensive income. These amounts were an unrealized gain of $- and $6,231 (net of effect of income tax expense of $-) for the years ended December 31, 2017 and 2016. Proceeds from the sale of marketable securities in the years ended December 31, 2017 and 2016 were $2,749,147 and $4,003,034. Net gains of $3,375 and net losses of $85 resulted from these sales for the years ended December 31, 2017 and 2016. |
Trade Receivables - Related Par
Trade Receivables - Related Party | 12 Months Ended |
Dec. 31, 2017 | |
Receivables [Abstract] | |
Trade Receivables - Related Party | Note 6 - Trade Receivables – Related Party Trade receivables – related party are made up of amounts due from Hainan Savy Akers Biosciences Ltd (“Hainan”), a joint venture between Akers, Thomas Knox, Akers’ former Board Chairman, and Hainan Savy Investment Management Ltd, located in the People’s Republic of China. The Company holds a 19.9% position in the joint venture. The amount due is non-interest bearing, unsecured and generally has a term of 30-90 days (Note 16). Credit terms of 180 days were extended to Hainan for a bulk purchase of BreathScan Breath Alcohol detectors during June 2017 while Hainan expands their market presence in the People’s Republic of China. |
Note Receivable _ Related Parti
Note Receivable – Related Parties | 12 Months Ended |
Dec. 31, 2017 | |
Note Receivable Related Parties | |
Note Receivable – Related Parties | Note 7 - Note Receivable – Related Parties On December 31, 2014, a note of $1,475,766 was issued to the Company in exchange for the Company’s open trade receivables from ChubeWorkx Guernsey Limited (“ChubeWorkx”), a major shareholder. It is payable in sixty equal installments of $27,734 commencing January 1, 2015 and has an interest rate of 5% per annum. As of December 31, 2015, the Company established an allowance for doubtful accounts for notes receivable – related party of $1,299,609 which is reported as bad debt expense – related parties in the Consolidated Statement of Operations and Comprehensive Loss for the year ended December 31, 2015. On August 17, 2016, the Company entered into a Settlement Agreement with ChubeWorkx which settled all pending claims between the companies. Under the terms of the Settlement Agreement, the Company recovered the full outstanding principal amount in the current fiscal year in the form of $750,000 of BreathScan® Alcohol Detector inventory – which the Company intends to subsequently sell – and the balance of $549,609 as a prepaid royalty (Note 16). As a result of the Settlement Agreement, the Company reversed the allowance for doubtful note in the amount of $1,299,609 which is included in the Consolidated Statement of Operations and Comprehensive Loss for the year ended December 31, 2016. For the period ending December 31, 2017 and 2016, the Company has invoiced $484,150 and $- for the BreathScan® Alcohol Detector inventory that was recovered as part of the Settlement. |
Inventories
Inventories | 12 Months Ended |
Dec. 31, 2017 | |
Inventory Disclosure [Abstract] | |
Inventories | Note 8 - Inventories Inventories consists of the following categories: December 31, 2017 2016 Raw Materials $ 458,441 $ 440,316 Sub-Assemblies 696,318 907,989 Finished Goods 720,951 749,488 Reserve for Obsolescence (30,429 ) (61,272 ) $ 1,845,281 $ 2,036,521 Obsolete inventory charged to cost of goods during the years ended December 31, 2017 and 2016 totaled $26,122 and $32,333. |
Property, Plant and Equipment
Property, Plant and Equipment | 12 Months Ended |
Dec. 31, 2017 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment | Note 9 - Property, Plant and Equipment Property, plant and equipment consists of the following: December 31, 2017 2016 Computer Equipment $ 114,771 $ 114,771 Computer Software 40,681 40,681 Office Equipment 39,959 39,959 Furniture & Fixtures 38,356 29,939 Machinery & Equipment 1,138,134 1,126,134 Molds & Dies 868,570 834,480 Leasehold Improvements 222,593 222,593 2,463,064 2,408,557 Less Accumulated Depreciation 2,227,951 2,149,165 $ 235,113 $ 259,392 Depreciation expenses totaled $78,786 and $115,054 for the years ended December 31, 2017 and 2016. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Note 10- Intangible Assets Intangible assets as of December 31, 2017 and 2016 and the movements for the periods then ended are as follows: Distributor & Patents & Customer Trademarks Relationships Totals Cost or Deemed Cost At December 31, 2015 $ 2,626,996 $ 1,270,639 $ 3,897,635 Additions - - - Disposals - - - At December 31, 2016 $ 2,626,996 $ 1,270,639 $ 3,897,635 Accumulated Amortization At December 31, 2015 $ 1,154,113 $ 1,270,639 $ 2,424,752 Amortization Charge 171,108 - 171,108 Disposals - - - At December 31, 2016 $ 1,325,221 $ 1,270,639 $ 2,595,860 Net Book Value At December 31, 2015 $ 1,472,883 $ - $ 1,472,883 At December 31, 2016 $ 1,301,775 $ - $ 1,301,775 Cost or Deemed Cost At December 31, 2016 $ 2,626,996 $ 1,270,639 $ 3,897,635 Additions - - - Disposals - - - At December 31, 2017 $ 2,626,996 $ 1,270,639 $ 3,897,635 Accumulated Amortization At December 31, 2016 $ 1,325,221 $ 1,270,639 $ 2,595,860 Amortization Charge 171,108 - 171,108 Disposals - - - At December 31, 2017 $ 1,496,329 $ 1,270,639 $ 2,766,968 Net Book Value At December 31, 2016 $ 1,301,775 $ - $ 1,301,775 At December 31, 2017 $ 1,130,667 $ - $ 1,130,667 Amortization expense totaled $171,108 for the years ended December 31, 2017 and 2016. The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows: Period Amount 2018 $ 171,108 2019 171,108 2020 171,108 2021 171,108 2022 171,108 |
Trade and Other Payables
Trade and Other Payables | 12 Months Ended |
Dec. 31, 2017 | |
Payables and Accruals [Abstract] | |
Trade and Other Payables | Note 11 - Trade and Other Payables Trade and other payables consists of the following: December 31, 2017 2016 Trade Payables $ 948,951 $ 923,311 Accrued Expenses 724,515 480,302 Deferred Compensation 59,750 59,750 $ 1,733,216 $ 1,463,363 Trade and other payables – related party are as follows: December 31, 2017 2016 Trade Payables $ 39,821 $ 182,001 Accrued Expenses - 52,066 $ 39,821 $ 234,067 As of December 31, 2017 the Company owed ChubeWorkx Guernsey Limited, previously a major shareholder, royalties of $36,661 (Note 16) which was paid on February 12, 2018. As of December 31, 2017, the Company owed Hainan $670. Senior management at Hainan are actively involved in Shenzhen Savy-Akers Biosciences (“Shenzhen”) which is therefore being included as a related party. The Company owed Shenzhen $2,490 as of December 31, 2017. Trade and other payables are non-interest bearing and are normally settled on 30 – 60 day terms. |
Share-based Payments
Share-based Payments | 12 Months Ended |
Dec. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Share-based Payments | Note 12 - Share-based Payments On January 23, 2014, upon effectiveness of the registration statement filed with the SEC, the Company adopted the 2013 Stock Incentive Plan (the “Plan”) which will provide for the issuance of up to 400,000 shares. The purpose of the Plan is to provide additional incentive to those officers, employees, consultants and non-employee directors of the Company and its parents, subsidiaries and affiliates whose contributions are essential to the growth and success of the Company’s business. On January 9, 2015, the Board of Directors of the Company approved, upon recommendation from the Compensation Committee of the Board, by unanimous written consent the Amended and Restated 2013 Incentive Stock and Award Plan (the “Amended Plan”), which increases the number of authorized shares of common stock subject to the Plan to 800,000 shares. On September 30, 2016, the Board of Directors increased the number of authorized shares of common stock subject to the Amended Plan to 830,000 shares. As of December 31, 2017, under the 2013 Amended Plan, grants of restricted stock and options to purchase 264,166 shares of common stock have been issued and are unvested or unexercised and 7,292 shares of common stock remain available for grants. On August 7, 2017, the Shareholders approved and the Company adopted the 2017 Equity Incentive Plan (the “Plan”) which will provide for the issuance of up to 1,350,000 shares. The purpose of the Plan is to provide additional incentive to those officers, employees, consultants and non-employee directors of the Company and its parents, subsidiaries and affiliates whose contributions are essential to the growth and success of the Company’s business. As of December 31, 2017, under the 2017 Plan, grants totaling 295,107 shares of restricted common stock have been issued and 1,054,893 shares of common stock remain available for grants. The Plan may be administered by the board or a board-appointed committee. Eligible recipients of option awards are employees, officers, consultants or directors (including non-employee directors) of the Company or of any parent, subsidiary or affiliate of the Company. The board has the authority to grant to any eligible recipient any options, restricted stock or other awards valued in whole or in part by reference to, or otherwise based on, the Company’s common stock. Qualified option holders may exercise their options at their discretion. Each option granted may be exchanged for a prescribed number of shares of common stock. On January 1, 2016, the Company approved the issuance of 12,500 options to purchase common shares to a key consultant for services at an exercise price of $3.70 per common share with vesting over one year. The options carry a five-year expiration. On August 9, 2016 the Company approved the issuance of 26,000 options to purchase common shares to two key employees at an exercise price of $3.25 per common share with vesting over two years. The options carry a five-year expiration. The options issued under the above plan were valued using a Black Scholes option pricing model. The assumptions utilized in calculating the value of the issued options under Black Scholes are as follows: 2017 2016 Expected option term - 5 yrs Expected volatility - 95.02 % Expected divident yeild - 0.00 % Risk free interest rate - 1.76 % The Company did not issue any options or warrants under the above plan during the year ended December 31, 2017. The following table summarizes the option activities for the years ended December 31, 2017 and 2016: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (years) Value Balance at December 31, 2015 220,500 $ 4.38 3.81 $ - Granted 38,500 3.40 4.43 - Exercised - - - - Forfeited - - - - Canceled/Expired - - - - Balance at December 31, 2016 259,000 $ 4.23 3.05 $ 20,100 Exercisable as of December 31, 2016 239,167 $ 4.31 2.92 $ 20,100 Balance at December 31, 2016 259,000 $ 4.23 3.05 $ 20,100 Granted - - - - Exercised - - - - Forfeited (4,000 ) 3.25 3.63 - Canceled/Expired - - - - Balance at December 31, 2017 255,000 $ 4.25 2.02 $ - Exercisable as of December 31, 2017 250,334 $ 4.27 1.99 $ - The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.13 and $1.90 for our common shares on December 31, 2017 and 2016. A summary of the Company’s non-vested shares as of December 31, 2017 and the changes during the period then ended are as follows: Weighted Average Grant Non-Vested Shares Shares Date Fair Value Non-vested at December 31, 2015 - $ - Granted 38,500 1.98 Vested (18,666 ) 1.90 Forfeited - - Non-vested at December 31, 2016 19,834 $ 2.36 Non-vested at December 31, 2016 19,834 $ 2.36 Granted - - Vested (11,168 ) 2.07 Forfeited (4,000 ) 2.36 Non-vested at December 31, 2017 4,666 $ 2.36 Unrecognized compensation cost related to non-vested employee stock options totaled $6,930 as of December 31, 2017. The cost is to be recognized over a weighted average period of 0.62 years. During the years ended December 31, 2017 and 2016, the Company incurred stock option expenses totaling $19,457 and $51,653. During the year ended December 31, 2017, the Company issued 50,415,571 warrants in conjunction with two public offerings and a private placement of the Company’s common shares. All warrants carry a five-year expiration term. The table below summarizes the warrant activity for the year ended December 31, 2017: Weighted Weighted Average Average Remaining Number of Exercise Contractual Warrants Price Term (years) Balance at December 31, 2016 - $ - - Granted 50,415,571 0.24 4.94 Exercised (925,000 ) 1.11 - Forfeited - - - Canceled/Expired - - - Balance at December 31, 2017 49,490,571 $ 0.22 4.95 Exercisable as of December 31, 2017 48,766,371 $ 0.22 4.95 |
Equity
Equity | 12 Months Ended |
Dec. 31, 2017 | |
Equity [Abstract] | |
Equity | Note 13 - Equity The holders of common shares are entitled to one vote per share at meetings of the Company. Holders of Series B convertible preferred shares have no voting rights at meetings of the Company. A restricted stock award is an award of common shares that are subject to certain restrictions during a specified period. Restricted stock awards are independent of option grants and are generally subject to forfeiture if employment terminates prior to the release of the restrictions. The grantee cannot transfer the shares before the restricted shares vest. Shares on non-vested restricted stock have the same voting rights as common stock, are entitled to receive dividends and other distributions thereon and are considered to be currently issued and outstanding. The Company expenses the cost of the restricted stock awards, which is determined to be the fair market value of the shares at the date of grant, straight-line over the period during which the restrictions lapse. For these purposes, the fair market value of the restricted stock is determined based on the closing price of the Company’s common stock on the grant date. On June 8, 2016, the Company issued 27,500 restricted common shares to an officer in connection with his employment agreement. These shares vest 1/3 immediately on the date of the grant and the remaining 2/3 vests equally on March 1, 2017 and March 1, 2018. The fair value of these shares was $54,725 and was based on the share price on the date of the grant. $21,103 and $30,153 was recorded during the years ended December 31, 2017 and 2016 as administrative expense on the Consolidated Statement of Operations and Comprehensive Loss and the remaining $3,469 is reported as deferred compensation, a contra equity account, on the Condensed Consolidated Balance Sheet as of December 31, 2017. On January 13, 2017, the Company completed a public offering of 1,789,500 common shares, raising net proceeds of $1,652,994. Below is a summary of the gross proceeds to net proceeds calculation. Shares $ $ Common Shares Base Offering 1,667,000 2,000,400 Over-Allotment 122,500 147,000 Gross Proceeds 2,147,400 Underwriter/Gunnar Expenses Discount 150,318 Legal Fees 60,000 Roadshow 1,783 Miscellaneous 34,005 Total 246,106 Akers Biosciences Expenses Legal & Accounting 197,813 Registration/Regulatory 50,487 Total 248,300 Net Proceeds 1,652,994 In addition to the common shares issued, the Company also issued 894,750 warrants with an exercise price of $1.50 per common share. All of the warrants issued have a five-year term. On March 30, 2017, the Company completed a private placement of 1,448,400 unregistered shares of common stock, raising net proceeds of $1,760,317. The unregistered shares were admitted to trading on September 30, 2017 upon notification from the Securities and Exchange Commission that the Registration Statement, filed April 19, 2017, had been deemed effective. Below is a summary of the gross proceeds to net proceeds calculation. Shares $ $ Common Shares Base Offering 1,448,400 2,027,760 Gross Proceeds 2,027,760 Underwriter/Gunnar Expenses Discount 141,943 Legal Fees 50,000 Total 191,943 Akers Biosciences Expenses Legal & Accounting 75,000 Filing Fees 500 Total 75,500 Net Proceeds 1,760,317 In addition to the common shares issued, the Company also issued 796,620 warrants with an exercise price of $1.96 per common share with a five-year term. On April 11, 2017, the Company issued 10,000 restricted shares to a consultant for services to be rendered during the year ending December 31, 2017. These shares vested on the date of the grant. The fair value of these shares was $18,000 and was based on the share price on the date of the grant. The company recorded $5,455 during the year ended December 31, 2017 as sales and marketing expenses on the Consolidated Statement of Operations and Comprehensive Loss. The Company will recognize the remaining expense of $12,545 during the year ending December 31, 2018. On October 12, 2017, the Company entered into Warrant Exercise Agreements with the existing holders of 724,200 warrants from the March 2017 private placement with an original exercise price of $1.96 per share to exercise their current warrants at $1.00 per share and receive a new warrant which would be convertible into the same number of common shares as the original warrant. The new warrant has an exercise price of $1.26 and expire five years from the date of issuance. The increase in fair value of the reduction in the exercise price of the warrants from $1.96 to $1.00 was $93,386. The Company used the Black-Scholes option pricing model to calculate the increase in fair value with the following assumptions for the decrease in exercise price: no dividend yield, expected volatility of 97.16%, risk free interest rate of 1.95%, and expected warrant life of 4.47 years. The fair value of the new warrants issued of 724,200 was $671,546. The Company used the Black-Scholes option pricing model to calculate the fair value with the following assumptions for the issuance of the new warrants: no dividend yield, expected volatility of 97.16%, risk free interest rate of 1.95%, and expected warrant life of 5 years. In accordance with FASB ASC 718-20-35, expenses related to the modification and re-issue of the warrants totaled $764,932 which are included as warrant modification expenses on the Consolidated Statement of Operations and Comprehensive Loss. The Company received net proceeds of $680,748 net of a solicitation fee of $43,452 from the exercise of 724,200 warrants. On October 17, 2017, the Board of Directors issued 295,107 restricted shares of common stock to key employees and officers of the Company as part of the 2017 Equity Incentive Plan. The restricted stock vested immediately and were valued at the closing stock price of $0.88 per share. The fair value of the restricted shares totaled $259,694 and were expensed immediately. The expense is included in the Consolidated Statement of Operations and Comprehensive Loss for the year ending December 31, 2017 as follows: Expense Category 2017 2016 General & Administrative $ 163,924 — Sales & Marketing 95,770 — $ 259,694 $ — On December 21, 2017, the Company completed a public offering of 21,500,000 common shares and 3,675 Series B convertible preferred shares, raising net proceeds of $6,065,586. Below is a summary of the gross proceeds to net proceeds calculation. Public Offering - December 21, 2017 Shares $ $ Common Shares Base Offering 15,500,000 2,325,000 Over-Allotment 6,000,000 900,000 Series B Preferred Shares Base Offering 3,675 3,675,000 Gross Proceeds 6,900,000 Underwriter/Gunnar Expenses Discount 483,000 Non-Accountable Allowance 60,000 Legal Fees 75,000 Roadshow 2,558 Miscellaneous 36,500 Total 657,058 Akers Biosciences Expenses Legal & Accounting 160,000 Registration/Regulatory 17,356 Total 177,356 Net Proceeds 6,065,586 In addition to the common shares issued, the Company also issued 46,000,001 warrants with an exercise price of $0.1875 per common share in support of the base offering. All the warrants issued have a five-year term. During the year ended December 31, 2017, warrant holders from the January 13, 2017 public offering executed 200,800 warrants with an exercise price of $1.50 per common share, raising net proceeds of $301,200. |
Loss Per Share
Loss Per Share | 12 Months Ended |
Dec. 31, 2017 | |
Earnings Per Share [Abstract] | |
Loss Per Share | Note 14 - Loss per share The calculation of basic and diluted loss per share at December 31, 2017 and 2016 was based on the loss attributable to common shareholders of $5,805,326 and $3,303,538. The basic and diluted weighted average number of common shares outstanding for 2017 and 2016 was 9,494,977 and 5,430,205. Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period. Potential common shares consist of options, warrants and unvested restricted stock. Diluted net loss per common share was the same as basic net loss per common share for the years ended December 31, 2017 and 2016 since the effect of options and warrants would be anti-dilutive due to the net loss attributable to the common shareholders. Instruments excluded from dilutive earnings per share, because their inclusion would be anti-dilutive, were as follows: incentive and award stock options – 255,000 and 259,000; unvested restricted shares of common stock – 9,166 and 18,333; warrants – 48,766,371 and - as of December 31, 2017 and 2016. |
Income Tax Expense
Income Tax Expense | 12 Months Ended |
Dec. 31, 2017 | |
Income Tax Disclosure [Abstract] | |
Income Tax Expense | Note 15 - Income Tax Expense The Company utilizes the asset and liability method of accounting for income taxes in accordance with FASB ASC 740. The Company’s income tax (benefit)/provision is as follows: Years Ended December 31, 2017 2016 Current $ - $ - Deferred (6,440,000 ) $ (751,000 ) Change in Valuation Allowance 6,440,000 $ 751,000 Income Tax Benefit $ - $ - The reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December 31, 2017 and 2016 are as follows: Years Ended December 31, 2017 2016 Statutory U.S. Federal Income Tax Rate (35.0 %) (35.0 %) New Jersey State income taxes, net of U.S. Federal tax effect (6.0 %) (6.0 %) Tax rate change 152.0 % 0.0 % Change in Valuation Allowance (111.0 )% 41.0 % Net 0.0 % 0.0 % In December 2017, the Tax Cuts and Jobs Act was enacted, which reduced the U.S. statutory corporate tax rate to 21% for tax years beginning in 2018. This change resulted in a re-measurement of the federal portion of the Company’s deferred tax assets and the valuation allowance as of December 31, 2017 from 35% to the new 21% tax rate. As of December 31, 2017 and 2016, the Company had Federal net operating loss carry forwards of approximately $68,600,000 and $60,100,000, expiring through the year ending December 31, 2037. As of December 31, 2017 and 2016, the Company had New Jersey state net operating loss carry forwards of approximately $17,800,000 and $9,400,000, expiring through the year ending December 31, 2024. The principle components of the deferred tax assets and related valuation allowances as of December 31, 2017 and 2016 are as follows: Years Ended December 31, 2017 2016 Reserves and other $ 387,000 $ 865,000 Net operating loss carry-forwards 15,656,000 21,618,000 Valuation Allowance (16,043,000 ) (22,483,000 ) Net $ - $ - The valuation allowance for deferred tax assets as of December 31, 2017 and 2016 was $16,043,000 and $22,483,000. The change in the total valuation for the years ended December 31, 2017 and 2016 were a decrease of $6,440,000 and an increase of $751,000. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the net operating losses and temporary differences become deductible. Management considered projected future taxable income and tax planning strategies in making this assessment. The value of the deferred tax assets was fully offset by a valuation allowance, due to the current uncertainty of the future realization of the deferred tax assets. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of January 1, 2017, the Company had no unrecognized tax benefits and no charge during 2017, and accordingly, the Company did not recognize any interest or penalties during 2017 related to unrecognized tax benefits. There is no accrual for uncertain tax positions as of December 31, 2017. The Company files U.S. federal income tax returns and a state income tax returns. The U.S. and state income tax returns filed for the tax years ending on December 31, 2014 and thereafter are subject to examination by the relevant taxing authorities. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2017 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 16 - Related Party Transactions On June 19, 2012, the Company entered into a 3-year exclusive License & Supply Agreement with ChubeWorkx Guernsey Limited (as successor to SONO International Limited) (“ChubeWorkx”) for the purchase and distribution of Akers’ proprietary breathalyzers outside North America. ChubeWorkx paid a licensing fee of $1,000,000 which was recognized over the term of the agreement through September 30, 2015. On June 13, 2013, the Company announced an expansion of the License and Supply Agreement with ChubeWorkx to include worldwide marketing and distribution of the “Be CHUBE” program using the Company’s breathalyzer. On August 17, 2016, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with ChubeWorkx Guernsey Limited (“ChubeWorkx”), a major shareholder, which settled all pending claims between the Company and ChubeWorkx. Specifically, the Company and ChubeWorkx agreed to voluntarily dismiss (i) the action in the United States Federal Court, District of New Jersey brought by the Company against ChubeWorkx for outstanding amounts due to the Company under a promissory note and (ii) the action in The High Court of Justice, Queen’s Bench Division Commercial Court, Royal Courts of Justice, United Kingdom brought by ChubeWorkx against the Company arising from an exclusive licensing agreement between ChubeWorkx and the Company (“Licensing Agreement”). Under the terms of the Settlement Agreement, the Company will recover the full outstanding principal amount in the current fiscal year in the form of $750,000 of BreathScan® Alcohol Detector inventory – which the Company intends to subsequently sell – and the balance of $549,609 as prepaid royalty. Akers’ established an allowance for this doubtful note in the Company’s financial statements for the year ended December 31, 2015. As a result of the Settlement Agreement, the Company reversed the allowance for doubtful note in the amount of $1,299,609 which was included in the Consolidated Statement of Operations and Comprehensive Loss for the year ended December 31, 2016. In addition to addressing the promissory note described above, the Settlement Agreement also allows the Company to market and sell all of the Company’s breath technology tests worldwide, unencumbered by any past/future claims by ChubeWorkx under the Licensing Agreement (entered into with ChubeWorkx in 2012 and subsequently amended in 2013). Under the terms of the Settlement Agreement, ChubeWorkx no longer holds any rights pertaining to Akers’ BreathScan® technology, which serves as the basis for a number of commercialized products including BreathScan® Alcohol Detector and BreathScan OxiChek™; and a number of products in development. In return for the Company regaining the full rights to sell breath technology products, under the terms of the Settlement Agreement, ChubeWorkx is entitled to receive a royalty of 5% of the Company’s gross revenues (the “ChubeWorkx Royalty”) until ChubeWorkx has earned an aggregate $5,000,000, after which point ChubeWorkx will no longer be entitled to receive any royalties from the Company and the Company shall have no further obligation to ChubeWorkx. The Settlement Agreement further allows the Company to retain 50% of the ChubeWorkx Royalty until the full $549,609 cash component of the monies owed by ChubeWorkx to the Company as described above has been satisfied. The Company recorded royalty expenses of $202,126 and $153,854 for the years ended December 31, 2017 and 2016 which are included in sales and marketing expenses – related party on the Consolidated Statement of Operations and Comprehensive Loss. As of December 31, 2017 and 2016, the Company owed ChubeWorkx royalties of $36,661 and $17,953. The royalty owing is subject to a monthly interest rate of 4.0% and is due in the month following the end of each quarter. Other terms of the Settlement include: 1) the pledge as security of all earned but unpaid royalties by the Company to ChubeWorkx all Company assets, worthy to satisfy its obligations, including all inventory and receivables, with the exception of (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; 2) the pledge as security of the settlement sum which remains unpaid by the Company to ChubeWorkx all Company (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; and 3) the grant of voting proxy by ChubeWorkx to the Company which allows the Company to vote ChubeWorkx’s shares for corporate formalities under certain conditions. The pledged assets are only at risk in the event that the Company cannot satisfy any outstanding royalty payment obligations subject to various cure periods and/or through a restructuring and/or liquidation under the United States Bankruptcy laws of the Company in favor of payment of said obligation. During the year ended December 31, 2017 and 2016, the Company invoiced $484,150 and $- for the BreathScan Breath Alcohol products acquired from the Settlement. The Company began purchasing manufacturing molds, plastic components and the assembled BreathScan Lync™ device through Hainan and its related party during the year ended December 31, 2016 (Note 11). The Company purchased a total of $41,731 and $207,135 during the years ended December 31, 2017 and 2016. As of December 31, 2017, the Company owed the Hainan and its related party $3,160 which is included in trade and other payables – related party on the Consolidated Balance Sheet. The amount owed is interest free and has similar credit terms as other suppliers. Trade receivables – related party as of December 31, 2017 and 2016 were $125,001 and $31,892. The amounts due are non-interest bearing, unsecured and generally have a term of 30-180 days (Note 6). Product revenue – related party for the years ended December 31, 2017 and 2016 were $124,631 and $380. The revenue was the result of sales to Hainan and its related party. |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments | Note 17 - Commitments The Company leases its facility in West Deptford, New Jersey under an operating lease (“Thorofare Lease”) with annual rentals of $132,000 plus common area maintenance (CAM) charges. The lease, which took effect on January 1, 2008, reduced the CAM charges allowing the Company to reach their own agreements with utilities and other maintenance providers. On January 7, 2013, the Company extended its lease agreement for a term of 7 years, expiring December 31, 2019. Rent expense for the Thorofare Lease, including related CAM charges for the years ended December 31, 2017 and 2016 totaled $161,807 and $161,160, respectively. The Company entered into a 24-month lease for a satellite office located in Ramsey, New Jersey (“Ramsey Lease”) with annual rents of $25,980 plus common area maintenance (CAM) charges. The lease took effect on June 1, 2017 and runs through May 31, 2019. Rent expenses for the Ramsey Lease, including related CAM charges totaled $15,166 and $- for the years ended December 31, 2017 and 2016. The Company posted a security deposit of $4,330 which is included in other assets on the Consolidated Balance Sheet. The Company entered into a 29-month lease for warehouse space located in Pitman, New Jersey (“Pitman Lease”) with annual rents of $39,650. The lease took effect on August 1, 2017 and runs through December 31, 2019. Rent expenses for the Pitman Lease totaled $16,670 and $- for the years ended December 31, 2017 and 2016. A security deposit of $4,950 is included in other assets on the Consolidated Balance Sheet. The Company entered into a 60-month operating lease for equipment with annual rentals of $6,156 on September 29, 2014. The lease commenced on October 21, 2014 upon the delivery of the equipment. The schedule of lease commitments is as follows: Thorofare Ramsey Pitman Equipment Lease Lease Lease Lease Total $ $ $ $ $ Next 12 Months 132,000 25,980 39,650 6,156 203,786 Next 13-24 Months 132,000 10,825 39,650 5,130 187,605 On June 30, 2017, the Company signed the Third Amendment to the exclusive Distribution Agreement with NovoTek Pharmaceuticals Limited (‘NovoTek’) which expanded the geographic area of coverage to include Poland and grants NovoTek the right to assemble certain PIFA Heparin PF/4 products in their facilities from components acquired from the Company. The Company has agreed to provide PIFA Heparin/PF4 devices, valued at approximately $90,000, at no charge to NovoTek for their use and are to be shipped upon their request. As of December 31, 2017, the Company had not shipped any goods related to the program. |
Major Customers
Major Customers | 12 Months Ended |
Dec. 31, 2017 | |
Major Customers [Abstract] | |
Major Customers | Note 18 - Major Customers For the year ended December 31, 2017, three customers generated 10% or more of the Company’s revenue. Sales to these customers accounted for 62% of the Company’s revenue. As of December 31, 2017, the amount due from these customers was $1,123,920. This concentration makes the Company vulnerable to a near-term severe impact should the relationships be terminated. For the year ended December 31, 2016, three customers generated 10% or more of the Company’s revenue. Sales to these customers accounted for 75% of the Company’s revenue. As of December 31, 2016, the amount due from these customers was $490,725. |
Major Suppliers
Major Suppliers | 12 Months Ended |
Dec. 31, 2017 | |
Major Suppliers [Abstract] | |
Major Suppliers | Note 19 - Major Suppliers For the year ended December 31, 2017, no suppliers accounted for 10% or more of the Company’s purchases. For the year ended December 31, 2016, one supplier accounted for 10% or more of the Company’s purchases. This supplier accounted for 27% of the Company’s total purchases. As of December 31, 2016, the amount due to this supplier was $164,049. |
Contingencies
Contingencies | 12 Months Ended |
Dec. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies | Note 20 – Contingencies On October 17, 2016 the Company was served with a notice that Pulse Health LLC (“Pulse”) filed a lawsuit against the Company on September 30, 2016 in United States Federal District Court, District of Oregon, alleging a breach of contract under the settlement agreement entered into by the Company and Pulse on April 8, 2011 which settled all claims and disputes between the Company and Pulse arising from a previously executed Technology Development Agreement entered into by the Company and Pulse and damages resulting from said alleged breach. Additionally, Pulse alleges false advertising and unlawful trade practices in connection with the Company’s sales activities related to the Company’s OxiChek™ products. The Company filed a series of motions with the Court seeking (1) to dismiss the Pulse complaint for lack of jurisdiction or, in the alternative, transfer the matter to the District Court for the District of New Jersey, Camden Vicinage and (2) to dismiss the unfair competition claims for failure to state a claim on which relief could be granted. Oral arguments on these motions were heard by the Court on March 10, 2017. The Court decided by order dated April 14, 2017 in favor of the Company and has dismissed with prejudice the claims brought by Pulse for unfair competition (both federal and state counts). The court decided against the Company in its motions for transfer of venue and for lack of jurisdiction. As such, the case shall proceed in the District Court of Oregon. Pulse subsequently filed an Amended Complaint, in which Pulse seeks not less than $500,000 in damages and, among other items, an injunction prohibiting the Company from manufacture, use and sale of the OxiChek product. The Company answered the Amended Complaint on May 11, 2017. Discovery concluded on January 22, 2018. The Court has received the Company’s summary judgment motion. A trial date may be set if Pulse’s last remaining claim for breach of contract survives the motion. The Company intends to establish a rigorous defense of all claims. The Company is unable to assess the potential outcome, so no accrual for losses was made as of December 31, 2017. All legal fees were expensed as and when incurred. |
Segment Information
Segment Information | 12 Months Ended |
Dec. 31, 2017 | |
Segment Reporting [Abstract] | |
Segment Information | Note 21 – Segment Information The Company is organized and operates as one operating segment. In accordance with FASB ASC 280 “Segment Reporting”, the Chief Operating Officer is the chief operating decision-maker who reviews operating results to make decisions on allocation of resources and assessment of performance for the entire company. The total revenue by different product lines was as follows: Years ended December 31, Product Line 2017 2016 MicroParticle Catalyzed Biosensor (“MPC”) $ 950,946 $ 282,516 Particle ImmunoFiltration Assay (“PIFA”) 2,232,684 2,577,148 Rapid Enzymatic Assay ("REA") 133,848 - Other 562,049 97,498 Product Revenue Total $ 3,879,527 $ 2,957,162 License Fees 50,000 3,750 Total Revenue $ 3,929,527 $ 2,960,912 The total revenue by geographic area determined based on the location of the customers was as follows: Years ended December 31, Geographic Region 2017 2016 United States $ 2,861,613 $ 2,330,723 People's Republic of China 627,132 502,998 Rest of World 440,782 127,191 Total Revenue $ 3,929,527 $ 2,960,912 The Company had long-lived assets totaling $59,830 and $61,081 located in the People’s Republic of China and $1,305,950 and $1,500,086 located in the United States as of December 31, 2017 and 2016, respectively. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2017 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 22 - Subsequent Events 1,755 shares of the Series B Convertible Preferred Stock converted to 11,700,002 shares of common stock during the period of January 2, 2018 through January 11, 2018. During the period January 17, 2018 through March 30, 2018, the Company received $5,717,345 from the exercise of 30,492,070 warrants. On March 27, 2018 the Company converted a trade receivable of $426,540 to a long-term note receivable with a term of 60 months and an interest rate of 4.25% per annum. The first installment on the note is due April 30, 2018. Included in the conversion is $365,298 that was included in trade receivables less an accrued rebate of $76,500 that was included in trade and other payables on the Consolidated Balance Sheet as of December 31, 2017. |
Significant Accounting Polici30
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Cash and Cash Equivalents | (a) Cash and Cash Equivalents Cash and cash equivalents comprise cash balances. The Company considers all highly liquid investments, which include short-term bank deposits (up to 3 months from date of deposit) that are not restricted as to withdrawal date or use, to be cash equivalents. Bank overdrafts are shown as part of trade and other payables in the consolidated balance sheet. |
Fair Value of Financial Instruments | (b) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables. The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their short maturities. The fair value of marketable securities is described in Note 3(c). |
Fair Value Measurement - Marketable Securities | (c) Fair Value Measurement – Marketable Securities The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows: Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 Inputs to the valuation methodology include ● quoted prices for similar assets or liabilities in active markets; ● quoted prices for identical or similar assets or liabilities in inactive markets; ● inputs other than quoted prices that are observable for the asset or liability; ● inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs. |
Trade Receivables, Trade Receivables - Related Party and Allowance for Doubtful Accounts | (d) Trade Receivables, Trade Receivables – Related Party and Allowance for Doubtful Accounts The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature. The normal credit terms extended to customers ranges between 30 and 90 days. Credit terms longer than these may be extended after considering the credit worthiness of the customers and the business requirements. The Company reviews all receivables that exceed terms and establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade and other receivables. A considerable amount of judgment is required in assessing the amount of allowance. The Company considers the historical level of credit losses, makes judgments about the credit worthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. As of December 31, 2017 and 2016, allowances for doubtful accounts for trade receivables were $596,196 and $1,010,196. Bad debt expenses for trade receivables were $494,436 and $146,196 for the years ended December 31, 2017 and 2016. The credit comprises the reversal of an allowance for bad debts expense – related party of $1,299,609 and an allowance for bad debts for an external party of $146,195 included in the administrative expenses for the year ended December 31, 2016. Included in the allowance for doubtful accounts as of December 31, 2016 is $864,000 being an allowance for doubtful account of a trade receivable from a related party written off against the trade receivable in the year ended December 31, 2017. As of December 31, 2017 and 2016, the aging of trade receivables and trade receivables – related party was as follows: December 31, Aging Period 2017 % 2016 % Current (Notes 6 & 16) 1,808,449 81 % 464,365 28 % 01-30 Days 79,535 4 % 43,223 3 % 31-60 Days 20,154 1 % 39,203 2 % 61-90 Days 25,100 1 % 6,150 0 % >90 Days 278,944 13 % 1,090,418 67 % Subtotal 2,212,182 1,643,359 Bad Debts Allowance (596,196 ) (1,010,196 ) Total $ 1,615,986 $ 633,163 Average Days in Receivable 205.48 202.58 The aging above represents the number of days that the account receivable balance exceeds the credit terms. Included in the current category is accounts receivable of $570,800 and $- as of December 31, 2017 and December 31, 2016 with payment terms extended to 180 days. |
Concentration of Credit Risk | (e) Concentration of Credit Risk The Company is exposed to credit risk in the normal course of business primarily related to trade receivables and cash and cash equivalents. All of the Company’s cash is maintained with Fulton Bank of New Jersey, Bank of America, NA and PayPal. The funds are insured by the FDIC up to a maximum of $250,000, but are otherwise unprotected. The Company placed $426,927 and $67,865 with Fulton Bank of New Jersey, $7,915 and $795 with Bank of America, NA and $3,590 and $4,040 with PayPal as of December 31, 2017 and 2016. No losses have been incurred in these accounts. Concentration of credit risk with respect to trade receivables exists as approximately 62% of the Company’s product revenue is generated by three customers. These customers accounted for 51% of trade receivables as of December 31, 2017. To limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition. |
Inventories | (f) Inventories Inventories are measured at the lower of cost or net realizable value. The cost of inventories is based on the weighted-average principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, costs include an appropriate share of production overheads based on normal operating capacity. |
Property, Plant and Equipment | (g) Property, Plant and Equipment Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized within “other income” in the consolidated statement of operations and comprehensive loss. Depreciation is recognized in profit and loss on the accelerated basis over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of the lease term or their useful lives. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Plant and equipment 5-12 Furniture and fixtures 5-10 Computer equipment & software 3-5 Shorter of the Leasehold Improvements remaining lease or estimated useful life Depreciation methods, useful lives and residual values are reviewed at each reporting date. |
Intangible Assets | (h) Intangible Assets (i) Patents and Trade Secrets The Company has developed or acquired several diagnostic tests that can detect the presence of various substances in a person’s breath, blood, urine and saliva. Propriety protection for the Company’s products, technology and process is important to its competitive position. As of December 31, 2017, the Company has ten patents from the United States Patent Office in effect (9,383,368; 7,896,167; 8,097,171; 8,003,061; 8,425,859; 8,871,521; 8,808,639; D691,056; D691,057 and D691,058). Other patents are in effect in Australia through the Design Registry (348,310; 348,311 and 348,312), European Union Patents 1793906, 2684025, 002216895-0001; 002216895-0002 and 002216895-0003), in Hong Kong (HK11004006) and in Japan (1,515,170; 4,885,134; 4,931,821 5,775,790, and 6023096). Patents are in the national phase of prosecution in many Patent Cooperation Treaty participating countries. Additional proprietary technology consists of numerous different inventions. The Company intends to file additional patent applications, where appropriate, relating to new products, technologies and their use in the U.S., European and Asian markets. Management intends to protect all other intellectual property (e.g. copyrights, trademarks and trade secrets) using all legal remedies available to the Company. (ii) Patent Costs Costs associated with applying for patents are capitalized as patent costs. Once the patents are approved, the respective costs are amortized over their estimated useful lives (maximum of 17 years) on a straight-line basis. Patent pending costs for patents that are not approved are charged to operations the year the patent is rejected. In addition, patents may be purchased from third parties. The costs of acquiring the patent are capitalized as patent costs if it represents a future economic benefit to the Company. Once a patent is acquired it is amortized over its remaining useful life. (iii) Other Intangible Assets Other intangible assets that are acquired by the Company, which have definite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses. (iv) Amortization Amortization is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use. The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Patents and trademarks 12-17 Customer lists 5 |
Recoverability of Long Lived Assets | (i) Recoverability of Long Lived Assets In accordance with FASB ASC 360-10-35 “Impairment or Disposal of Long-lived Assets”, long-lived assets to be held and used are analyzed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable or that the useful lives of those assets are no longer appropriate. The Company evaluates at each balance sheet date whether events and circumstances have occurred that indicate possible impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted and without interest charges) and comparing such amount to the carrying amount of the assets. An impairment loss, if one exists, is then measured as the amount by which the carrying amount of the asset exceeds the discounted estimated future cash flows. Assets to be disposed of are reported at the lower of the carrying amount or fair value of such assets less costs to sell. Asset impairment charges are recorded to reduce the carrying amount of the long-lived asset that will be sold or disposed of to their estimated fair values. Charges for the asset impairment reduce the carrying amount of the long-lived assets to their estimated salvage value in connection with the decision to dispose of such assets. |
Investments | (j) Investments In accordance with FASB ASC 323, the Company recognizes investments in joint ventures based upon the Company’s ability to significantly influence the operational or financial policies of the joint venture. An objective judgment of the level of influence is made at the time of the investment based upon several factors including, but not limited to the following: a) Representation on the Board of Directors b) Participation in policy-making processes c) Material intra-entity transactions d) Interchange of management personnel e) Technological dependencies f) Extent of ownership and the ability to influence decision making based upon the makeup of other owners when the shareholder group is small. The Company follows the equity method for valuating investments in joint ventures when the existence of significant influence over operational and financial policy has been established, as determined by management; otherwise, the Company will valuate these investments using the cost method. Investments recorded using the cost method will be assessed for any decrease in value that has occurred that is other than temporary and the other than temporary decrease in value shall be recognized. As and when circumstances and facts change, the Company will evaluate the Company’s ability to significantly influence operational and financial policy to establish a basis for converting the investment accounted for using the cost method to the equity method of valuation. On March 9, 2015, the Company contributed capital of $64,675 in Hainan Savy Akers Biosciences, Ltd., a company incorporated in the People’s Republic of China, resulting in a 19.9% ownership interest. The contribution was adjusted downward to $64,091 on April 8, 2015; the net effect of the currency conversion when the contribution was processed in Hainan. This is included in other assets in the Consolidated Balance Sheet as of December 31, 2017 and 2016 and is accounted for using the cost method. |
Revenue Recognition | (k) Revenue Recognition In accordance with FASB ASC 605, the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) the collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales when title passes to the customer based on shipping terms. The Company typically does not accept returns nor offer charge backs or rebates except for certain distributors. Revenue recorded is net of any discount, rebate or sales return. The accrual for estimated sales returns was $- as of December 31, 2017 and 2016. The Company implemented a standard dealer cost model during the year ended December 31, 2016 which includes a provision for rebates to the distributors under limited circumstances. The Company established an accrual of $126,471 and $41,120, which is a reduction of revenue as of December 31, 2017 and 2016. Accounts receivable will be reduced when the rebates are applied by the customer. The Company recognized $372,664 and $471,949 during the years ended December 31, 2017 and 2016 for rebates, which is included as a reduction of product revenue in the Consolidated Statement of Operations and Comprehensive Loss. License fee revenue is recognized on a straight-line basis over the term of the license agreement. When the Company enters into arrangements that contain more than one deliverable, the Company allocates revenue to the separate elements under the arrangement based on their relative selling prices in accordance with FASB ASC 605-25. |
Income Taxes | (l) Income Taxes The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense or benefit is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. |
Shipping and Handling Fees and Costs | (m) Shipping and Handling Fees and Costs The Company charges actual shipping plus a handling fee to customers, which amounted to $62,049 and $54,928 for the years ended December 31, 2017 and 2016. These fees are classified as part of product revenue in the Consolidated Statement of Operations and Comprehensive Loss. Shipping and other related delivery costs, including those for incoming raw materials are classified as part of the cost of net revenue, which amounted to $136,145 and $138,662 for the years ended December 31, 2017 and 2016. |
Research and Development Costs | (n) Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred. |
Stock-based Payments | (o) Stock-based Payments The Company accounts for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over shorter of the period over which services are to be received or the vesting period. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees”. Under FASB ASC 505-50, the Company determines the fair value of the stock warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The Company estimates the fair value of stock-based awards to non-employees on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the period which services are to be received. At the end of each financial reporting period, prior to vesting or prior to completion of services, the fair value of equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurement until the equity based payments are fully vested or the service is completed. |
Basic and Diluted Earnings Per Share of Common Stock | (p) Basic and Diluted Earnings per Share of Common Stock Basic earnings per common share are based on the weighted average number of shares outstanding during the periods presented. Diluted earnings per share are computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive, i.e. the exercise prices of the outstanding stock options were greater than the market price of the common stock. |
Recently Adopted Accounting Pronouncements | (q) Recently Adopted Accounting Pronouncements As of December 31, 2017 and for the year then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements. |
Recently Issued Accounting Pronouncements Not Yet Adopted | (r) Recently Issued Accounting Pronouncements Not Yet Adopted As the Company is an emerging growth company, it has elected to adopt recently issued standards based on effective dates applicable to nonpublic entities. All effective dates as mentioned in the following paragraphs refer to that applicable to nonpublic entities. In May 2014 and April 2016, the FASB issued ASU No. 2014-09 and ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, FASB issued ASU 2015-14 which deferred the effective date of Update 2014-09 to annual reporting periods beginning after December 15, 2018 and interim reporting periods within annual reporting periods beginning after December 15, 2019. Early application is permitted as of annual reporting periods beginning after December 15, 2016 including interim reporting periods within that reporting period. The Company is currently evaluating the effect of the amendments but it does not anticipate a material impact of its financial statements. The Company expects to use the modified retrospective adoption method. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments – Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation |
Significant Accounting Polici31
Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Schedule of Trade Receivables and Trade Receivables - Related Parties | As of December 31, 2017 and 2016, the aging of trade receivables and trade receivables – related party was as follows: December 31, Aging Period 2017 % 2016 % Current (Notes 6 & 16) 1,808,449 81 % 464,365 28 % 01-30 Days 79,535 4 % 43,223 3 % 31-60 Days 20,154 1 % 39,203 2 % 61-90 Days 25,100 1 % 6,150 0 % >90 Days 278,944 13 % 1,090,418 67 % Subtotal 2,212,182 1,643,359 Bad Debts Allowance (596,196 ) (1,010,196 ) Total $ 1,615,986 $ 633,163 Average Days in Receivable 205.48 202.58 |
Schedule of Estimated Useful Life of Property Plant and Equipment | The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Plant and equipment 5-12 Furniture and fixtures 5-10 Computer equipment & software 3-5 Shorter of the Leasehold Improvements remaining lease or estimated useful life |
Schedule of Estimated Useful Lives for Current and Comparative Period | The estimated useful lives for the current and comparative periods are as follows: Useful Life (in years) Patents and trademarks 12-17 Customer lists 5 |
Fair Value Measurement - Mark32
Fair Value Measurement - Marketable Securities (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Investments, Debt and Equity Securities [Abstract] | |
Schedule of Marketable Securities | This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings. As of December 31, 2017 Accrued Unrealized Unrealized Fair Cost Income Gains Losses Value Level 2: Money market funds $ 5,165 $ 161 $ - $ - $ 5,326 Municipal securities 5,005,000 1,281 - - 5,006,281 Total Level 2: 5,010,165 1,442 - - 5,011,607 Total: $ 5,010,165 $ 1,442 $ - $ - $ 5,011,607 As of December 31, 2016 Cost Accrued Income Unrealized Gains Unrealized Losses Fair Value Level 2: Money market funds $ 29,657 $ 15 $ - $ - $ 29,672 Municipal securities 20,314 15 - - 20,329 Total Level 2: 49,971 30 - - 50,001 Total: $ 49,971 $ 30 $ - $ - $ 50,001 |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | Inventories consists of the following categories: December 31, 2017 2016 Raw Materials $ 458,441 $ 440,316 Sub-Assemblies 696,318 907,989 Finished Goods 720,951 749,488 Reserve for Obsolescence (30,429 ) (61,272 ) $ 1,845,281 $ 2,036,521 |
Property, Plant and Equipment (
Property, Plant and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Plant and Equipment | Property, plant and equipment consists of the following: December 31, 2017 2016 Computer Equipment $ 114,771 $ 114,771 Computer Software 40,681 40,681 Office Equipment 39,959 39,959 Furniture & Fixtures 38,356 29,939 Machinery & Equipment 1,138,134 1,126,134 Molds & Dies 868,570 834,480 Leasehold Improvements 222,593 222,593 2,463,064 2,408,557 Less Accumulated Depreciation 2,227,951 2,149,165 $ 235,113 $ 259,392 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Finite-Lived Intangible Assets | Intangible assets as of December 31, 2017 and 2016 and the movements for the periods then ended are as follows: Distributor & Patents & Customer Trademarks Relationships Totals Cost or Deemed Cost At December 31, 2015 $ 2,626,996 $ 1,270,639 $ 3,897,635 Additions - - - Disposals - - - At December 31, 2016 $ 2,626,996 $ 1,270,639 $ 3,897,635 Accumulated Amortization At December 31, 2015 $ 1,154,113 $ 1,270,639 $ 2,424,752 Amortization Charge 171,108 - 171,108 Disposals - - - At December 31, 2016 $ 1,325,221 $ 1,270,639 $ 2,595,860 Net Book Value At December 31, 2015 $ 1,472,883 $ - $ 1,472,883 At December 31, 2016 $ 1,301,775 $ - $ 1,301,775 Cost or Deemed Cost At December 31, 2016 $ 2,626,996 $ 1,270,639 $ 3,897,635 Additions - - - Disposals - - - At December 31, 2017 $ 2,626,996 $ 1,270,639 $ 3,897,635 Accumulated Amortization At December 31, 2016 $ 1,325,221 $ 1,270,639 $ 2,595,860 Amortization Charge 171,108 - 171,108 Disposals - - - At December 31, 2017 $ 1,496,329 $ 1,270,639 $ 2,766,968 Net Book Value At December 31, 2016 $ 1,301,775 $ - $ 1,301,775 At December 31, 2017 $ 1,130,667 $ - $ 1,130,667 |
Schedule of Estimated Aggregate Amortization Expense of Fiscal Years | The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows: Period Amount 2018 $ 171,108 2019 171,108 2020 171,108 2021 171,108 2022 171,108 |
Trade and Other Payables (Table
Trade and Other Payables (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Payables and Accruals [Abstract] | |
Schedule of Trade and Other Payable | Trade and other payables consists of the following: December 31, 2017 2016 Trade Payables $ 948,951 $ 923,311 Accrued Expenses 724,515 480,302 Deferred Compensation 59,750 59,750 $ 1,733,216 $ 1,463,363 |
Schedule of Trade and Other Payables - Related Party | Trade and other payables – related party are as follows: December 31, 2017 2016 Trade Payables $ 39,821 $ 182,001 Accrued Expenses - 52,066 $ 39,821 $ 234,067 |
Share-based Payments (Tables)
Share-based Payments (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of Options and Warrants Valuation Assumptions Under Black Scholes Pricing Model | The options issued under the above plan were valued using a Black Scholes option pricing model. The assumptions utilized in calculating the value of the issued options under Black Scholes are as follows: 2017 2016 Expected option term - 5 yrs Expected volatility - 95.02 % Expected divident yeild - 0.00 % Risk free interest rate - 1.76 % |
Summary of Stock Options Activity | The following table summarizes the option activities for the years ended December 31, 2017 and 2016: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (years) Value Balance at December 31, 2015 220,500 $ 4.38 3.81 $ - Granted 38,500 3.40 4.43 - Exercised - - - - Forfeited - - - - Canceled/Expired - - - - Balance at December 31, 2016 259,000 $ 4.23 3.05 $ 20,100 Exercisable as of December 31, 2016 239,167 $ 4.31 2.92 $ 20,100 Balance at December 31, 2016 259,000 $ 4.23 3.05 $ 20,100 Granted - - - - Exercised - - - - Forfeited (4,000 ) 3.25 3.63 - Canceled/Expired - - - - Balance at December 31, 2017 255,000 $ 4.25 2.02 $ - Exercisable as of December 31, 2017 250,334 $ 4.27 1.99 $ - |
Schedule of Non Vested Share Activity | A summary of the Company’s non-vested shares as of December 31, 2017 and the changes during the period then ended are as follows: Weighted Average Grant Non-Vested Shares Shares Date Fair Value Non-vested at December 31, 2015 - $ - Granted 38,500 1.98 Vested (18,666 ) 1.90 Forfeited - - Non-vested at December 31, 2016 19,834 $ 2.36 Non-vested at December 31, 2016 19,834 $ 2.36 Granted - - Vested (11,168 ) 2.07 Forfeited (4,000 ) 2.36 Non-vested at December 31, 2017 4,666 $ 2.36 |
Summary of Warrant Activity | The table below summarizes the warrant activity for the year ended December 31, 2017: Weighted Weighted Average Average Remaining Number of Exercise Contractual Warrants Price Term (years) Balance at December 31, 2016 - $ - - Granted 50,415,571 0.24 4.94 Exercised (925,000 ) 1.11 - Forfeited - - - Canceled/Expired - - - Balance at December 31, 2017 49,490,571 $ 0.22 4.95 Exercisable as of December 31, 2017 48,766,371 $ 0.22 4.95 |
Equity (Tables)
Equity (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Equity [Abstract] | |
Schedule of Proceeds from Initial Public Offering | Below is a summary of the gross proceeds to net proceeds calculation. Shares $ $ Common Shares Base Offering 1,667,000 2,000,400 Over-Allotment 122,500 147,000 Gross Proceeds 2,147,400 Underwriter/Gunnar Expenses Discount 150,318 Legal Fees 60,000 Roadshow 1,783 Miscellaneous 34,005 Total 246,106 Akers Biosciences Expenses Legal & Accounting 197,813 Registration/Regulatory 50,487 Total 248,300 Net Proceeds 1,652,994 Below is a summary of the gross proceeds to net proceeds calculation. Shares $ $ Common Shares Base Offering 1,448,400 2,027,760 Gross Proceeds 2,027,760 Underwriter/Gunnar Expenses Discount 141,943 Legal Fees 50,000 Total 191,943 Akers Biosciences Expenses Legal & Accounting 75,000 Filing Fees 500 Total 75,500 Net Proceeds 1,760,317 Below is a summary of the gross proceeds to net proceeds calculation. Public Offering - December 21, 2017 Shares $ $ Common Shares Base Offering 15,500,000 2,325,000 Over-Allotment 6,000,000 900,000 Series B Preferred Shares Base Offering 3,675 3,675,000 Gross Proceeds 6,900,000 Underwriter/Gunnar Expenses Discount 483,000 Non-Accountable Allowance 60,000 Legal Fees 75,000 Roadshow 2,558 Miscellaneous 36,500 Total 657,058 Akers Biosciences Expenses Legal & Accounting 160,000 Registration/Regulatory 17,356 Total 177,356 Net Proceeds 6,065,586 |
Schedule of Expenses Related to Grants | The expense is included in the Consolidated Statement of Operations and Comprehensive Loss for the year ending December 31, 2017 as follows: Expense Category 2017 2016 General & Administrative $ 163,924 — Sales & Marketing 95,770 — $ 259,694 $ — |
Income Tax Expense (Tables)
Income Tax Expense (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income Tax Benefit (Provision) | The Company’s income tax (benefit)/provision is as follows: Years Ended December 31, 2017 2016 Current $ - $ - Deferred (6,440,000 ) $ (751,000 ) Change in Valuation Allowance 6,440,000 $ 751,000 Income Tax Benefit $ - $ - |
Schedule of Reconciliation of Income Taxes using Statutory U.S. Income Tax Rate and Benefit from Income Taxes | The reconciliation of income taxes using the statutory U.S. income tax rate and the benefit from income taxes for the years ended December 31, 2017 and 2016 are as follows: Years Ended December 31, 2017 2016 Statutory U.S. Federal Income Tax Rate (35.0 %) (35.0 %) New Jersey State income taxes, net of U.S. Federal tax effect (6.0 %) (6.0 %) Tax rate change 152.0 % 0.0 % Change in Valuation Allowance (111.0 )% 41.0 % Net 0.0 % 0.0 % |
Schedule of Deferred Tax Assets and Related Valuation Allowances | The principle components of the deferred tax assets and related valuation allowances as of December 31, 2017 and 2016 are as follows: Years Ended December 31, 2017 2016 Reserves and other $ 387,000 $ 865,000 Net operating loss carry-forwards 15,656,000 21,618,000 Valuation Allowance (16,043,000 ) (22,483,000 ) Net $ - $ - |
Commitments (Tables)
Commitments (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Lease Commitments | The schedule of lease commitments is as follows: Thorofare Ramsey Pitman Equipment Lease Lease Lease Lease Total $ $ $ $ $ Next 12 Months 132,000 25,980 39,650 6,156 203,786 Next 13-24 Months 132,000 10,825 39,650 5,130 187,605 |
Segment Information (Tables)
Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Segment Reporting [Abstract] | |
Schedule of Revenue by Different Product Lines | The total revenue by different product lines was as follows: Years ended December 31, Product Line 2017 2016 MicroParticle Catalyzed Biosensor (“MPC”) $ 950,946 $ 282,516 Particle ImmunoFiltration Assay (“PIFA”) 2,232,684 2,577,148 Rapid Enzymatic Assay ("REA") 133,848 - Other 562,049 97,498 Product Revenue Total $ 3,879,527 $ 2,957,162 License Fees 50,000 3,750 Total Revenue $ 3,929,527 $ 2,960,912 |
Schedule of Revenue by Geographic Area Determined Based on Location of Customers | The total revenue by geographic area determined based on the location of the customers was as follows: Years ended December 31, Geographic Region 2017 2016 United States $ 2,861,613 $ 2,330,723 People's Republic of China 627,132 502,998 Rest of World 440,782 127,191 Total Revenue $ 3,929,527 $ 2,960,912 |
Significant Accounting Polici42
Significant Accounting Policies (Details Narrative) | Aug. 08, 2015USD ($) | Mar. 09, 2015USD ($) | Dec. 31, 2017USD ($)Breathlyzers | Dec. 31, 2016USD ($) |
Allowances for doubtful accounts for trade receivables | $ 596,196 | $ 1,010,196 | ||
Bad debt expenses | 494,436 | 146,196 | ||
Reversal of allowance for bad debts expense - related party | 1,299,609 | |||
Allowance for bad debts for external party | 146,195 | |||
Accounts receivable, related parties | 570,800 | |||
Deferred revenue | 126,471 | 41,120 | ||
Revenue recognition rebates expense | 372,664 | 471,949 | ||
Shipping, handling and transportation costs | 62,049 | 54,928 | ||
Cost of net revenue | $ 136,145 | 138,662 | ||
Percentage for deferred tax balances valuation allowance | 100.00% | |||
Hainan Savy Akers Biosciences, Ltd. [Member] | ||||
Contributed capital | $ 64,091 | $ 64,675 | ||
Ownership percentage | 19.90% | |||
Patents [Member] | ||||
Number of patents | Breathlyzers | 10 | |||
Trade Receivable [Member] | Three Customers [Member] | ||||
Concentration risk percentage | 62.00% | |||
Concentration risk, number of customer | Breathlyzers | 3 | |||
Related Party [Member] | ||||
Allowances for doubtful accounts for trade receivables | 864,000 | |||
Fulton Bank of New Jersey [Member] | ||||
Cash | $ 426,927 | 67,865 | ||
Bank of America [Member] | ||||
Cash | 7,915 | 795 | ||
PayPal [Member] | ||||
Cash | $ 3,590 | $ 4,040 | ||
Minimum [Member] | ||||
Normal credit terms extended to customers | 30 days | |||
Maximum [Member] | ||||
Normal credit terms extended to customers | 90 days | |||
Cash, FDIC insured amount | $ 250,000 | |||
Maximum [Member] | Patents [Member] | ||||
Finite-lived intangible asset, useful life | 17 years |
Significant Accounting Polici43
Significant Accounting Policies - Schedule of Trade Receivables and Trade Receivables - Related Parties (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Trade Receivables | $ 1,490,985 | $ 601,271 |
Subtotal | 2,212,182 | 1,643,359 |
Bad Debts Allowance | (596,196) | (1,010,196) |
Total | $ 1,615,986 | $ 633,163 |
Average Days in Receivables | 205.48 Days | 202.58 Days |
Current (Notes 6 & 16) [Member] | ||
Trade Receivables | $ 1,808,449 | $ 464,365 |
Percentage of Trade Receivables | 81.00% | 28.00% |
01-30 Days [Member] | ||
Trade Receivables | $ 79,535 | $ 43,223 |
Percentage of Trade Receivables | 4.00% | 3.00% |
31-60 Days [Member] | ||
Trade Receivables | $ 20,154 | $ 39,203 |
Percentage of Trade Receivables | 1.00% | 2.00% |
61-90 Days [Member] | ||
Trade Receivables | $ 25,100 | $ 6,150 |
Percentage of Trade Receivables | 1.00% | 0.00% |
Greater Than 90 [Member] | ||
Trade Receivables | $ 278,944 | $ 1,090,418 |
Percentage of Trade Receivables | 13.00% | 67.00% |
Significant Accounting Polici44
Significant Accounting Policies - Schedule of Estimated Useful Life of Property Plant and Equipment (Details) | 12 Months Ended |
Dec. 31, 2017 | |
Plant and Equipment [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 5 years |
Plant and Equipment [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 12 years |
Furniture & Fixtures [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 5 years |
Furniture & Fixtures [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 10 years |
Computer Equipment & Software [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 3 years |
Computer Equipment & Software [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 5 years |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life Description | Shorter of the remaining lease or estimated useful life |
Significant Accounting Polici45
Significant Accounting Policies - Schedule of Estimated Useful Lives for Current and Comparative Period (Details) | 12 Months Ended |
Dec. 31, 2017 | |
Patents and Trademarks [Member] | Minimum [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 12 years |
Patents and Trademarks [Member] | Maximum [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 17 years |
Customer Lists [Member] | |
Finite-Lived Intangible Assets [Line Items] | |
Finite-lived intangible asset, useful life | 5 years |
Management Plan (Details Narrat
Management Plan (Details Narrative) - USD ($) | Dec. 21, 2017 | Jan. 13, 2017 | Mar. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Proceeds from public offering | $ 6,065,586 | $ 1,652,994 | $ 1,760,317 | $ 9,478,897 | ||
Additional expenses from exercise of warrants | 981,948 | |||||
Reduction in weekly operating cash, percentage | 19.00% | |||||
Reduction in weekly operating cash, amount | $ 80,253 | $ 98,699 | ||||
Weekly operating cash requirement increased | 97,700 | $ 80,253 | ||||
Minimum [Member] | ||||||
Weekly cash requirements | 95,000 | |||||
Maximum [Member] | ||||||
Weekly cash requirements | 100,000 | |||||
March 16, 2018 [Member] | ||||||
Cash and marketable securities | 8,940,000 | |||||
Working capital | 11,640,000 | |||||
March 16, 2018 [Member] | Private Placement [Member] | ||||||
Additional expenses from exercise of warrants | $ 4,909,081 |
Fair Value Measurement - Mark47
Fair Value Measurement - Marketable Securities (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Investments, Debt and Equity Securities [Abstract] | ||
Maturities of securities | 1 year | |
Unrealized gains/(losses) on marketable securities | $ 6,231 | |
Income tax expense | ||
Proceeds from the sale of marketable securities | 2,749,147 | 4,003,034 |
Net gain on securities | 3,375 | 3,375 |
Net loss on securities | $ 85 | $ 85 |
Fair Value Measurement - Mark48
Fair Value Measurement - Marketable Securities - Schedule of Marketable Securities (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Schedule of Available-for-sale Securities [Line Items] | ||
Cost | $ 5,010,165 | $ 49,971 |
Accrued Income | 1,442 | 30 |
Unrealized Gains | ||
Unrealized Losses | ||
Fair Value | 5,011,607 | 50,001 |
Fair Value, Inputs, Level 2 [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Cost | 5,010,165 | 49,971 |
Accrued Income | 1,442 | 30 |
Unrealized Gains | ||
Unrealized Losses | ||
Fair Value | 5,011,607 | 50,001 |
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Cost | 5,165 | 29,657 |
Accrued Income | 161 | 15 |
Unrealized Gains | ||
Unrealized Losses | ||
Fair Value | 5,326 | 29,672 |
Fair Value, Inputs, Level 2 [Member] | Municipal Securities [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Cost | 5,005,000 | 20,314 |
Accrued Income | 1,281 | 15 |
Unrealized Gains | ||
Unrealized Losses | ||
Fair Value | $ 5,006,281 | $ 20,329 |
Trade Receivables - Related P49
Trade Receivables - Related Parties (Details Narrative) | 12 Months Ended |
Dec. 31, 2017 | |
Minimum [Member] | |
Trade and other payables are non-interest bearing, terms | 30 days |
Maximum [Member] | |
Trade and other payables are non-interest bearing, terms | 60 days |
Hainan [Member] | Minimum [Member] | |
Trade and other payables are non-interest bearing, terms | 30 days |
Hainan [Member] | Maximum [Member] | |
Trade and other payables are non-interest bearing, terms | 90 days |
Hainan [Member] | People's Republic of China [Member] | |
Equity interest percentage | 19.90% |
Note Receivable _ Related Par50
Note Receivable – Related Parties (Details Narrative) | Jan. 02, 2015USD ($)Breathlyzers | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | Aug. 17, 2016USD ($) | Dec. 31, 2014USD ($) |
(Reversal of Allowance for) Bad Debt Expenses - Related parties | $ 1,299,609 | $ 1,299,609 | ||||
Chubeworkx Guernsey Limited [Member] | ||||||
Notes receivables related party | $ 1,475,766 | |||||
Number of installments | Breathlyzers | 60 | |||||
Installment amount of note receivable | $ 27,734 | |||||
Interest rate on notes payable | 5.00% | |||||
Chubeworkx Guernsey Limited [Member] | Settlement Agreement [Member] | ||||||
Notes receivables related party | $ 549,609 | |||||
Prepaid royalties | $ 750,000 | |||||
BreathScan Breath Alcohol [Member] | Settlement Agreement [Member] | ||||||
Proceeds from productive assets | $ 484,150 |
Inventories (Details Narrative)
Inventories (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Inventory Disclosure [Abstract] | ||
Cost of goods sold for obsolete inventory | $ 26,122 | $ 32,333 |
Inventories - Schedule of Inven
Inventories - Schedule of Inventories (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Inventory Disclosure [Abstract] | ||
Raw Materials | $ 458,441 | $ 440,316 |
Sub-Assemblies | 696,318 | 907,989 |
Finished Goods | 720,951 | 749,488 |
Reserve for Obsolescence | (30,429) | (61,272) |
Inventory, Net, Total | $ 1,845,281 | $ 2,036,521 |
Property, Plant and Equipment53
Property, Plant and Equipment (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation expense | $ 78,786 | $ 115,054 |
Property, Plant and Equipment -
Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | $ 2,463,064 | $ 2,408,557 |
Accumulated Depreciation | 2,227,951 | 2,149,165 |
Property, Plant and Equipment, Net | 235,113 | 259,392 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | 114,771 | 114,771 |
Computer Software [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | 40,681 | 40,681 |
Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | 39,959 | 39,959 |
Furniture & Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | 38,356 | 29,939 |
Machinery & Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | 1,138,134 | 1,126,134 |
Molds & Dies [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | 868,570 | 834,480 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, Plant and Equipment | $ 222,593 | $ 222,593 |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Amortization expense | $ 171,108 | $ 171,108 |
Intangible Assets - Schedule o
Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Finite-Lived Intangible Assets [Line Items] | ||
Cost or Deemed Cost, Beginning Balance | $ 3,897,635 | $ 3,897,635 |
Cost or Deemed Cost, Additions | ||
Cost or Deemed Cost, Disposals | ||
Cost or Deemed Cost, Ending Balance | 3,897,635 | 3,897,635 |
Accumulated Amortization, Beginning Balance | 2,595,860 | 2,424,752 |
Accumulated Amortization, Amortization Charge | 171,108 | 171,108 |
Accumulated Amortization, Disposals | ||
Accumulated Amortization, Ending Balance | 2,766,968 | 2,595,860 |
Net Book Value, Beginning Balance | 1,301,775 | 1,472,883 |
Net Book Value, Ending Balance | 1,130,667 | 1,301,775 |
Patents & Trademarks [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost or Deemed Cost, Beginning Balance | 2,626,996 | 2,626,996 |
Cost or Deemed Cost, Additions | ||
Cost or Deemed Cost, Disposals | ||
Cost or Deemed Cost, Ending Balance | 2,626,996 | 2,626,996 |
Accumulated Amortization, Beginning Balance | 1,325,221 | 1,154,113 |
Accumulated Amortization, Amortization Charge | 171,108 | 171,108 |
Accumulated Amortization, Disposals | ||
Accumulated Amortization, Ending Balance | 1,496,329 | 1,325,221 |
Net Book Value, Beginning Balance | 1,301,775 | 1,472,883 |
Net Book Value, Ending Balance | 1,130,667 | 1,301,775 |
Distributor & Customer Relationships [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost or Deemed Cost, Beginning Balance | 1,270,639 | 1,270,639 |
Cost or Deemed Cost, Additions | ||
Cost or Deemed Cost, Disposals | ||
Cost or Deemed Cost, Ending Balance | 1,270,639 | 1,270,639 |
Accumulated Amortization, Beginning Balance | 1,270,639 | 1,270,639 |
Accumulated Amortization, Amortization Charge | ||
Accumulated Amortization, Disposals | ||
Accumulated Amortization, Ending Balance | 1,270,639 | 1,270,639 |
Net Book Value, Beginning Balance | ||
Net Book Value, Ending Balance |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Estimated Aggregate Amortization Expense of Fiscal Years (Details) | Dec. 31, 2017USD ($) |
Goodwill and Intangible Assets Disclosure [Abstract] | |
2,017 | $ 171,108 |
2,018 | 171,108 |
2,019 | 171,108 |
2,020 | 171,108 |
2,021 | $ 171,108 |
Trade and Other Payables (Detai
Trade and Other Payables (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Royalty expenses | $ 202,126 | $ 153,854 |
Minimum [Member] | ||
Trade and other payables are non-interest bearing, terms | 30 days | |
Maximum [Member] | ||
Trade and other payables are non-interest bearing, terms | 60 days | |
ChubeWorkx [Member] | February 12, 2018 [Member] | ||
Royalty expenses | $ 36,661 | |
Hainan [Member] | ||
Due to related parties owned | 670 | |
Shenzhen Savy-Akers Biosciences [Member] | ||
Due to related parties owned | $ 2,490 |
Trade and Other Payables - Sche
Trade and Other Payables - Schedule of Trade and Other Payable (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Payables and Accruals [Abstract] | ||
Trade Payables | $ 948,951 | $ 923,311 |
Accrued Expenses | 724,515 | 480,302 |
Deferred Compensation | 59,750 | 59,750 |
Trade and Other Payables, Total | $ 1,733,216 | $ 1,463,363 |
Trade and Other Payables - Sc60
Trade and Other Payables - Schedule of Trade and Other Payables - Related Party (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Payables and Accruals [Abstract] | ||
Trade Payables | $ 39,821 | $ 182,001 |
Accrued Expenses | 52,066 | |
Trade and Other Payables - Related Party | $ 39,821 | $ 234,067 |
Share-based Payments (Details N
Share-based Payments (Details Narrative) - USD ($) | Aug. 07, 2017 | Aug. 09, 2016 | Jan. 02, 2016 | Jan. 23, 2014 | Dec. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jan. 09, 2015 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of stock option issued | 38,500 | |||||||
Stock option exercise price | $ 3.40 | |||||||
Aggregate intrinsic value exercise price of options | $ 0.13 | $ 1.90 | ||||||
Unrecognized compensation cost | $ 6,930 | |||||||
Unrecognized compensation weighted average period | 7 months 13 days | |||||||
Stock options expenses | $ 19,457 | $ 51,653 | ||||||
Key Consultant [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of stock option issued | 12,500 | |||||||
Stock option exercise price | $ 3.70 | |||||||
Vesting period | 1 year | |||||||
Stock option, expire term | 5 years | |||||||
Key Consultant [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of stock option issued | 26,000 | |||||||
Stock option exercise price | $ 3.25 | |||||||
Vesting period | 2 years | |||||||
Stock option, expire term | 5 years | |||||||
Public Offering [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of warrants issued during the period | 50,415,571 | |||||||
Warrant term | 5 years | |||||||
Board Of Directors [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of shares authorized during period | 830,000 | |||||||
Amended And Restated 2013 Incentive Stock And Award Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of shares authorized during period | 800,000 | |||||||
2013 Amended Plan [Member] | Restricted Stock [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of stock option to purchase shares of common stock | 264,166 | |||||||
2013 Amended Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of available for grants | 7,292 | |||||||
2017 Equity Incentive Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of available for grants | 1,054,893 | |||||||
Number of grants totaling shares of restricted common stock | 295,107 | |||||||
Maximum [Member] | 2013 Stock Incentive Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of stock option issued | 400,000 | |||||||
Maximum [Member] | 2017 Equity Incentive Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Number of stock option issued | 135,000 |
Share-based Payments - Schedule
Share-based Payments - Schedule of Options and Warrants Valuation Assumptions Under Black Scholes Pricing Model (Details) | 12 Months Ended |
Dec. 31, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Expected option term | 5 years |
Expected volatility | 95.02% |
Expected divident yeild | 0.00% |
Risk free interest rate | 1.76% |
Share-based Payments - Summary
Share-based Payments - Summary of Stock Options Activity (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Number of Shares, Beginning | 259,000 | 220,500 |
Number of Shares, Granted | 38,500 | |
Number of Shares, Exercised | ||
Number of Shares, Forfeited | (4,000) | |
Number of Shares, Cancelled/Expired | ||
Number of Shares, Ending | 255,000 | 259,000 |
Number of Shares, Exercisable | 250,334 | 239,167 |
Weighted Average Exercise Price, Beginning | $ 4.23 | $ 4.38 |
Weighted Average Exercise Price, Granted | 3.40 | |
Weighted Average Exercise Price, Exercised | ||
Weighted Average Exercise Price, Forfeited | 3.25 | |
Weighted Average Exercise Price, Cancelled/Expired | ||
Weighted Average Exercise Price, Ending | 4.25 | 4.23 |
Weighted Average Exercise Price, Exercisable | $ 4.27 | $ 4.31 |
Weighted Average Remaining Contractual Term, Beginning | 3 years 18 days | 3 years 9 months 22 days |
Weighted Average Remaining Contractual Term, Granted | 0 years | 4 years 5 months 5 days |
Weighted Average Remaining Contractual Term, Exercised | 0 years | 0 years |
Weighted Average Remaining Contractual Term, Forfeited | 3 years 7 months 17 days | 0 years |
Weighted Average Remaining Contractual Term, Cancelled/Expired | 0 years | 0 years |
Weighted Average Remaining Contractual Term, Ending | 2 years 7 days | 3 years 18 days |
Weighted Average Remaining Contractual Term, Exercisable | 1 year 11 months 26 days | 2 years 11 months 1 day |
Aggregate Intrinsic Value, Beginning | $ 20,100 | |
Aggregate Intrinsic Value, Ending | 20,100 | |
Aggregate Intrinsic Value, Exercisable | $ 20,100 |
Share-based Payments - Schedu64
Share-based Payments - Schedule of Non Vested Share Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Number of Shares Non-vested, beginning | 19,834 | |
Number of Shares, Granted | 38,500 | |
Number of Shares, Vested | (11,168) | (18,666) |
Number of Shares, Forfeited | (4,000) | |
Number of Shares, Non-vested, ending | 4,666 | 19,834 |
Weighted Average Grant Date Fair Value, beginning | $ 2.36 | |
Weighted Average Grant Date Fair Value, Granted | 1.98 | |
Weighted Average Grant Date Fair Value, Vested | 2.07 | 1.90 |
Weighted Average Grant Date Fair Value, Forfeited | 2.36 | |
Weighted Average Grant Date Fair Value, ending | $ 2.36 | $ 2.36 |
Share-based Payments - Summar65
Share-based Payments - Summary of Warrant Activity (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Number of Warrants, Granted | 38,500 | |
Number of Warrants, Exercised | ||
Number of Warrants, Forfeited | (4,000) | |
Number of Warrants, Cancelled/Expired | ||
Weighted Average Exercise Price, Beginning | $ 4.23 | $ 4.38 |
Weighted Average Exercise Price, Granted | 3.40 | |
Weighted Average Exercise Price, Exercised | ||
Weighted Average Exercise Price, Forfeited | 3.25 | |
Weighted Average Exercise Price, Cancelled/Expired | ||
Weighted Average Exercise Price, Ending | 4.25 | 4.23 |
Weighted Average Exercise Price, Exercisable | $ 4.27 | $ 4.31 |
Weighted Average Remaining Contractual Term, Beginning | 3 years 18 days | 3 years 9 months 22 days |
Weighted Average Remaining Contractual Term, Granted | 0 years | 4 years 5 months 5 days |
Weighted Average Remaining Contractual Term, Ending | 2 years 7 days | 3 years 18 days |
Weighted Average Remaining Contractual Term, Exercisable | 1 year 11 months 26 days | 2 years 11 months 1 day |
Warrants [Member] | ||
Number of Warrants, Beginning | ||
Number of Warrants, Granted | 50,415,571 | |
Number of Warrants, Exercised | (925,000) | |
Number of Warrants, Forfeited | ||
Number of Warrants, Cancelled/Expired | ||
Number of Warrants, Ending | 49,490,571 | |
Number of Warrants, Exercisable | 48,766.371 | |
Weighted Average Exercise Price, Beginning | ||
Weighted Average Exercise Price, Granted | 0.24 | |
Weighted Average Exercise Price, Exercised | 1.11 | |
Weighted Average Exercise Price, Forfeited | ||
Weighted Average Exercise Price, Cancelled/Expired | ||
Weighted Average Exercise Price, Ending | 0.22 | |
Weighted Average Exercise Price, Exercisable | $ 0.22 | |
Weighted Average Remaining Contractual Term, Beginning | 0 years | |
Weighted Average Remaining Contractual Term, Granted | 4 years 11 months 8 days | |
Weighted Average Remaining Contractual Term, Ending | 4 years 11 months 12 days | |
Weighted Average Remaining Contractual Term, Exercisable | 4 years 11 months 12 days |
Equity (Details Narrative)
Equity (Details Narrative) - USD ($) | Dec. 21, 2017 | Oct. 17, 2017 | Oct. 12, 2017 | Apr. 11, 2017 | Mar. 31, 2017 | Mar. 30, 2017 | Jan. 13, 2017 | Jun. 08, 2016 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 |
Administrative expense | $ 4,082,313 | $ 3,008,811 | |||||||||
Deferred compensation | 3,469 | $ 24,572 | |||||||||
Number of common shares | 1,789,500 | ||||||||||
Issuance of common stock | $ 1,652,994 | $ 1,652,994 | |||||||||
Number of warrant issued during period | 894,750 | ||||||||||
Warrant exercise price | $ 1.50 | ||||||||||
Dividend yield | 0.00% | ||||||||||
Expected volatility | 95.02% | ||||||||||
Risk free interest rate | 1.76% | ||||||||||
Expected life | 5 years | ||||||||||
Sales and marketing expense | $ 1,846,445 | $ 1,983,428 | |||||||||
Expenses related to the grants | $ 259,694 | ||||||||||
Preferred shares, issued | 1,755 | 0 | |||||||||
Net proceeds from issuance of shares | $ 3,675,000 | ||||||||||
Common stock, reserved shares | 61,445,573 | ||||||||||
Current Warrant [Member] | |||||||||||
Warrant exercise price | $ 1 | ||||||||||
New Warrant [Member] | |||||||||||
Warrant exercise price | $ 1.26 | ||||||||||
Warrant term | 5 years | ||||||||||
Proceeds from issuance of warrants | $ 671,546 | ||||||||||
Dividend yield | 0.00% | ||||||||||
Expected volatility | 97.16% | ||||||||||
Risk free interest rate | 1.95% | ||||||||||
Expected life | 5 years | ||||||||||
Warrants [Member] | |||||||||||
Number of warrant issued during period | 460,000,001 | ||||||||||
Warrant exercise price | $ 0.1875 | ||||||||||
Warrant term | 5 years | ||||||||||
Fair value of warrants | $ 93,386 | ||||||||||
Dividend yield | 0.00% | ||||||||||
Expected volatility | 97.16% | ||||||||||
Risk free interest rate | 1.95% | ||||||||||
Expected life | 4 years 5 months 19 days | ||||||||||
Warrants [Member] | Maximum [Member] | |||||||||||
Warrant exercise price | $ 1.96 | ||||||||||
Warrants [Member] | Minimum [Member] | |||||||||||
Warrant exercise price | $ 1 | ||||||||||
Warrant Exercise Agreement [Member] | |||||||||||
Number of warrant issued during period | 724,200 | ||||||||||
Warrant exercise price | $ 1.96 | ||||||||||
Proceeds from issuance of warrants | $ 680,748 | ||||||||||
Other extraordinary expenses | 764,932 | ||||||||||
Proceeds from net of solicitation fee | $ 43,452 | ||||||||||
Restricted Stock [Member] | |||||||||||
Fair value of shares based on share price on date of grant | $ 18,000 | ||||||||||
Number of warrant issued during period | 37,500 | ||||||||||
Warrant exercise price | $ 1.50 | ||||||||||
Proceeds from issuance of warrants | $ 56,250 | ||||||||||
Number of shares issued for services | 10,000 | ||||||||||
Sales and marketing expense | $ 5,455 | ||||||||||
Shares issued, price per share | $ 0.88 | ||||||||||
Expenses related to the grants | 259,694 | ||||||||||
Restricted Stock [Member] | Key Employees and Officers [Member] | |||||||||||
Number of common shares | 295,107 | ||||||||||
Restricted Stock [Member] | December 31, 2018 [Member] | |||||||||||
Sales and marketing expense | $ 12,545 | ||||||||||
Public Offering [Member] | |||||||||||
Number of common shares | 21,500,000 | ||||||||||
Number of warrant issued during period | 163,300 | 200,800 | |||||||||
Warrant exercise price | $ 1.50 | $ 1.50 | |||||||||
Warrant term | 5 years | ||||||||||
Proceeds from issuance of warrants | $ 244,950 | $ 301,200 | |||||||||
Public Offering [Member] | Series B Preferred Shares [Member] | |||||||||||
Preferred shares, issued | 3,675 | ||||||||||
Net proceeds from issuance of shares | $ 6,065,586 | ||||||||||
Private Placement [Member] | |||||||||||
Number of warrant issued during period | 796,620 | ||||||||||
Warrant exercise price | $ 1.96 | ||||||||||
Warrant term | 5 years | ||||||||||
Unregistered shares of common stock | 1,448,400 | ||||||||||
Proceeds from unregistered shares | $ 1,760,317 | ||||||||||
Administrative Expenses [Member] | |||||||||||
Administrative expense | $ 21,103 | $ 30,153 | |||||||||
Officer [Member] | |||||||||||
Number of restricted common stock shares issued during the period | 27,500 | ||||||||||
Stock options vested rights description | These shares vest 1/3 immediately on the date of the grant and the remaining 2/3 vests equally on March 1, 2017 and March 1, 2018. | ||||||||||
Fair value of shares based on share price on date of grant | $ 54,725 |
Equity - Schedule of Proceeds F
Equity - Schedule of Proceeds From Initial Public Offering (Details) - USD ($) | Dec. 21, 2017 | Jan. 13, 2017 | Mar. 31, 2017 | Mar. 30, 2017 | Dec. 31, 2017 |
Number of common shares | 1,789,500 | ||||
Number of common shares, value | $ 1,652,994 | $ 1,652,994 | |||
Payments of Stock Issuance Costs | $ 177,356 | 248,300 | $ 75,500 | ||
Net Proceeds | 6,065,586 | 1,652,994 | 1,760,317 | $ 9,478,897 | |
Underwriter And Gunnar Expenses [Member] | |||||
Payments of Stock Issuance Costs | 657,058 | 246,106 | 191,943 | ||
Underwriter And Gunnar Expenses [Member] | Underwriter Discount [Member] | |||||
Payments of Stock Issuance Costs | 483,000 | 150,318 | 141,943 | ||
Underwriter And Gunnar Expenses [Member] | Gunnar Roadshow [Member] | |||||
Payments of Stock Issuance Costs | 2,558 | 1,783 | |||
Underwriter And Gunnar Expenses [Member] | Gunnar Miscellaneous [Member] | |||||
Payments of Stock Issuance Costs | 36,500 | 34,005 | |||
Underwriter And Gunnar Expenses [Member] | Underwriter Legal Fees [Member] | |||||
Payments of Stock Issuance Costs | 50,000 | ||||
Underwriter And Gunnar Expenses [Member] | Non - Accountable Allowance [Member] | |||||
Payments of Stock Issuance Costs | 60,000 | ||||
Parent Company Expenses [Member] | Legal Accounting Expenses [Member] | |||||
Payments of Stock Issuance Costs | 160,000 | 197,813 | $ 75,000 | ||
Parent Company Expenses [Member] | Registration Expenses [Member] | |||||
Payments of Stock Issuance Costs | 17,356 | 50,487 | |||
Parent Company Expenses [Member] | Filing Fees [Member] | |||||
Payments of Stock Issuance Costs | $ 500 | ||||
Common Shares [Member] | |||||
Gross Proceeds | $ 6,900,000 | $ 2,147,400 | $ 2,027,760 | ||
Common Shares [Member] | Base Offering [Member] | |||||
Number of common shares | 15,500,000 | 1,667,000 | 1,448,400 | ||
Number of common shares, value | $ 2,325,000 | $ 2,000,400 | $ 2,027,760 | ||
Common Shares [Member] | Over-Allotment [Member] | |||||
Number of common shares | 6,000,000 | 122,500 | |||
Number of common shares, value | $ 900,000 | $ 147,000 | |||
Underwriter Legal Fees [Member] | Underwriter And Gunnar Expenses [Member] | |||||
Payments of Stock Issuance Costs | $ 75,000 | $ 60,000 | |||
Series B Preferred Shares [Member] | Base Offering [Member] | |||||
Number of common shares | 3,675 | ||||
Number of common shares, value | $ 3,675,000 |
Equity - Schedule of Expenses R
Equity - Schedule of Expenses Related to Grants (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Expenses related to grants | $ 259,694 | |
General and Administrative Expenses [Member] | ||
Expenses related to grants | 163,924 | |
Sales and Marketing Expenses [Member] | ||
Expenses related to grants | $ 95,770 |
Loss Per Share (Details Narrati
Loss Per Share (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Net loss attributable to common stockholders | $ 5,805,326 | $ 3,303,538 |
Basic and diluted weighted average number of common shares outstanding | 9,494,977 | 5,430,205 |
Stock Option [Member] | ||
Anti-dilutive securities excluded from earning per share | 255,000 | 259,000 |
Restricted Stock [Member] | ||
Anti-dilutive securities excluded from earning per share | 9,166 | 18,333 |
Warrant [Member] | ||
Anti-dilutive securities excluded from earning per share | 48,766,371 |
Income Tax Expense (Details Nar
Income Tax Expense (Details Narrative) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Statutory corporate tax rate | 0.00% | 0.00% |
Valuation allowance for deferred tax assets | $ 16,043,000 | $ 23,483,000 |
Change in valuation allowance | 6,440,000 | 751,000 |
Unrecognized tax benefits | ||
Interest or penalties on unrecognized tax benefits | ||
Uncertain tax positions, accrued | ||
Tax Cuts and Jobs Act [Member] | ||
Income tax description | Tax Cuts and Jobs Act was enacted, which reduced the U.S. statutory corporate tax rate to 21% for tax years beginning in 2018. This change resulted in a re-measurement of the federal portion of the Companys deferred tax assets and the valuation allowance as of December 31, 2017 from 35% to the new 21% tax rate. | |
Statutory corporate tax rate | 21.00% | |
Federal [Member] | ||
Net operating loss carry forwards | $ 68,600,000 | 60,100,000 |
Operating loss carryforwards expiration date | Dec. 31, 2037 | |
New Jersey State [Member] | ||
Net operating loss carry forwards | $ 9,400,000 | $ 9,400,000 |
Operating loss carryforwards expiration date | Dec. 31, 2024 |
Income Tax Expense - Schedule o
Income Tax Expense - Schedule of Income Tax Benefit (Provision) (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Income Tax Disclosure [Abstract] | ||
Current | ||
Deferred | (6,440,000) | (751,000) |
Change in Valuation Allowance | 6,440,000 | 751,000 |
Income Tax Benefit |
Income Tax Expense - Schedule72
Income Tax Expense - Schedule of Reconciliation of Income Taxes using Statutory U.S. Income Tax Rate and Benefit from Income Taxes (Details) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Income Tax Disclosure [Abstract] | ||
Statutory U.S. Federal Income Tax Rate | (35.00%) | (35.00%) |
New Jersey State income taxes, net of U.S. | 0.00% | 0.00% |
Federal tax effect | (6.00%) | (6.00%) |
Tax rate change | 152.00% | 0.00% |
Change in Valuation Allowance | (111.00%) | 41.00% |
Net | 0.00% | 0.00% |
Income Tax Expense - Schedule73
Income Tax Expense - Schedule of Deferred Tax Assets and Related Valuation Allowances (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Income Tax Disclosure [Abstract] | ||
Reserves and other | $ 387,000 | $ 865,000 |
Net operating loss carry-forwards | 15,656,000 | 21,618,000 |
Valuation Allowance | (16,043,000) | (22,483,000) |
Net |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | Jun. 19, 2012 | Dec. 31, 2017 | Dec. 31, 2016 |
Related Party Transaction [Line Items] | |||
Exclusive license and supply agreement term | 3 years | ||
License fees received | $ 1,000,000 | ||
Royalty expenses | $ 202,126 | $ 153,854 | |
Payments to acquire plastic and electronic components | 41,731 | 207,135 | |
Trade and other payables | 3,160 | ||
Trade receivables related party | 125,001 | 31,892 | |
Product revenue from related party | 124,631 | 380 | |
ChubeWorkx [Member] | |||
Related Party Transaction [Line Items] | |||
Royalty owed | $ 36,661 | $ 17,953 | |
Monthly interest rate of royalties due | 4.00% | 4.00% | |
Settlement Agreement [Member] | |||
Related Party Transaction [Line Items] | |||
Recover full outstanding principal amount | $ 750,000 | ||
Proceeds from notes payable | $ 549,609 | ||
Allowance for doubtful note | $ 1,299,609 | ||
Settlement Agreement [Member] | ChubeWorkx [Member] | |||
Related Party Transaction [Line Items] | |||
Percentage of royalty received | 5.00% | ||
Royalty revenue | $ 5,000,000 | ||
Percentage of royalty retain | 50.00% | ||
Due to related parties owned | $ 549,609 | ||
Settlement Agreement [Member] | BreathScan Breath Alcohol [Member] | |||
Related Party Transaction [Line Items] | |||
Proceeds from productive assets | $ 484,150 |
Commitments (Details Narrative)
Commitments (Details Narrative) - USD ($) | Aug. 02, 2017 | Jun. 02, 2017 | Sep. 29, 2014 | Jan. 07, 2013 | Jan. 01, 2008 | Dec. 31, 2017 | Dec. 31, 2016 |
Operating leases rent expense, net | $ 39,650 | $ 25,980 | $ 6,156 | $ 132,000 | |||
Lease agreement term | 29 months | 24 months | 60 months | 7 years | |||
Lease expiration date | Dec. 31, 2019 | May 31, 2019 | Dec. 31, 2019 | ||||
NovoTek Pharmaceuticals Limited [Member] | |||||||
Payment agreed under agreement, value | $ 90,000 | ||||||
Thorofare Lease [Member] | |||||||
Rent expense, including related CAM charges | 161,807 | $ 161,160 | |||||
Ramsey Lease [Member] | |||||||
Rent expense, including related CAM charges | 15,166 | ||||||
Security deposit | 4,330 | ||||||
Pitman Lease [Member] | |||||||
Rent expense, including related CAM charges | 16,670 | ||||||
Security deposit | $ 4,950 |
Commitments - Schedule of Lease
Commitments - Schedule of Lease Commitments (Details) | Dec. 31, 2017USD ($) |
Next 12 Months | $ 203,786 |
Next 13-24 Months | 187,605 |
Thorofare Lease [Member] | |
Next 12 Months | 132,000 |
Next 13-24 Months | 132,000 |
Ramsey Lease [Member] | |
Next 12 Months | 25,980 |
Next 13-24 Months | 10,825 |
Pitman Lease [Member] | |
Next 12 Months | 39,650 |
Next 13-24 Months | 39,650 |
Equipment Lease [Member] | |
Next 12 Months | 6,156 |
Next 13-24 Months | $ 5,130 |
Major Customers (Details Narrat
Major Customers (Details Narrative) - Customers Three [Member] | 12 Months Ended | |
Dec. 31, 2017USD ($)Breathlyzers | Dec. 31, 2016USD ($)Breathlyzers | |
Concentration risk, percentage | 10.00% | 10.00% |
Concentration risk, number of customer | Breathlyzers | 3 | 3 |
Due from customers | $ | $ 1,123,920 | $ 490,725 |
Sales Revenue, Net [Member] | ||
Concentration risk, percentage | 62.00% | 75.00% |
Major Suppliers (Details Narrat
Major Suppliers (Details Narrative) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016USD ($)Breathlyzers | |
No Suppliers [Member] | ||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||
Concentration risk, percentage | 10.00% | |
One Supplier [Member] | ||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||
Concentration risk, percentage | 10.00% | |
Due to suppliers | $ | $ 164,049 | |
One Supplier [Member] | Accounts Payable [Member] | ||
Share-based Goods and Nonemployee Services Transaction [Line Items] | ||
Concentration risk, percentage | 27.00% | |
Concentration risk, number of suppliers | Breathlyzers | 1 |
Contingencies (Details Narrativ
Contingencies (Details Narrative) | Oct. 17, 2016USD ($) |
Pulse Health LLC [Member] | Maximum [Member] | |
Contingency damages seeking amount | $ 500,000 |
Segment Information (Details Na
Segment Information (Details Narrative) | 12 Months Ended | |
Dec. 31, 2017USD ($)Breathlyzers | Dec. 31, 2016USD ($) | |
Number of operating segments | Breathlyzers | 1 | |
People's Republic of China [Member] | ||
Long-lived assets | $ 59,830 | $ 61,081 |
United States [Member] | ||
Long-lived assets | $ 1,305,950 | $ 1,500,086 |
Segment Information - Schedule
Segment Information - Schedule of Revenue by Different Product Lines (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Product Revenue Total | $ 3,879,527 | $ 2,957,162 |
License Fees | 50,000 | 3,750 |
Total Revenue | 3,929,527 | 2,960,912 |
MicroParticle Calalyzed Biosensor ("MPC") [Member] | ||
Product Revenue Total | 950,946 | 282,516 |
Particle ImmunoFiltration Assay ("PIFA") [Member] | ||
Product Revenue Total | 2,232,684 | 2,577,148 |
Rapid Enzymatic Assay ("REA") [Member] | ||
Product Revenue Total | 133,848 | |
Other [Member] | ||
Product Revenue Total | $ 562,049 | $ 97,498 |
Segment Information - Schedul82
Segment Information - Schedule of Revenue by Geographic Area Determined Based on Location of Customers (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Total Revenue | $ 3,929,527 | $ 2,960,912 |
United States [Member] | ||
Total Revenue | 2,861,613 | 2,330,723 |
People's Republic of China [Member] | ||
Total Revenue | 627,132 | 502,998 |
Rest of World [Member] | ||
Total Revenue | $ 440,782 | $ 127,191 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | Mar. 27, 2018 | Jan. 11, 2018 | Mar. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Proceeds from exercise of warrants | $ 981,948 | ||||
Subsequent Event [Member] | |||||
Common stock issued for conversion | 11,700,002 | ||||
long-term note receivable | $ 426,540 | ||||
Debt instrument interest rate | 4.25% | ||||
Note maturity date | Apr. 30, 2018 | ||||
Note conversion net of earned rebate included in trade receivables | $ 365,298 | ||||
Accrued rebate | $ 76,500 | ||||
Subsequent Event [Member] | Warrants [Member] | |||||
Proceeds from exercise of warrants | $ 5,717,345 | ||||
Number of warrants exercised | 30,492,070 | ||||
Subsequent Event [Member] | Series B Convertible Preferred Stock [Member] | |||||
Conversion of preferred stock, shares | 1,755 |